HU000027890T2

(19) **HU**

(11) Lajstromszám: **E 027 890**

(13) **T2**

MAGYARORSZÁG
Szellemi Tulajdon Nemzeti Hivatala

EURÓPAI SZABADALOM
SZÖVEGÉNEK FORDÍTÁSA

(21) Magyar ügyszám: **E 07 786063**
(22) A bejelentés napja: **2007. 07. 13.**

(96) Az európai bejelentés bejelentési száma:
EP 20070786063
(97) Az európai bejelentés közzétételi adatai:
EP 2044079 A1 **2008. 01. 31.**
(97) Az európai szabadalom megadásának meghirdetési adatai:
EP 2044079 B1 **2015. 12. 09.**

(51) Int. Cl.: ***C07D 491/22*** *(2006.01)*
A61K 3147/45 *(2006.01)*
A61P 35/00 *(2006.01)*

(86) A nemzetközi (PCT) bejelentési szám:
PCT/EP 07/006243
(87) A nemzetközi közzétételi szám:
WO 08011994

(30) Elsőbbségi adatok:
MI20061473 **2006. 07. 26.** **IT**

(72) Feltaláló(k):
FONTANA, Gabriele, I-20139 Milano (IT)
BOMBARDELLI, Ezio, I-27027 Groppello Cairoli (IT)
MANZOTTI, Carla, I-20139 Milano (IT)
BATTAGLIA, Arturo, I-40129 Bologna (IT)
SAMORI, Cristian, I-47100 Forli (IT)

(73) Jogosult(ak):
Indena S.p.A., 20139 Milano (IT)

(74) Képviselő:
Danubia Szabadalmi és Jogi Iroda Kft., Budapest

(54) **Tumorellenes aktivitású kamptotecin-származékok**

Az európai szabadalom ellen, megadásának az Európai Szabadalmi Közlönyben való meghirdetésétől számított kilenc hónapon belül, felszólalást lehet benyújtani az Európai Szabadalmi Hivatalnál. (Európai Szabadalmi Egyezmény 99. cikk(1))

A fordítást a szabadalmas az 1995. évi XXXIII. törvény 84/H. §-a szerint nyújtotta be. A fordítás tartalmi helyességét a Szellemi Tulajdon Nemzeti Hivatala nem vizsgálta.

(19) Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) EP 2 044 079 B1

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention of the grant of the patent:
09.12.2015 Bulletin 2015/50

(21) Application number: **07786063.3**

(22) Date of filing: **13.07.2007**

(51) Int Cl.:
C07D 491/22 *(2006.01)* ***A61K 31/4745*** *(2006.01)*
A61P 35/00 *(2006.01)*

(86) International application number:
PCT/EP2007/006243

(87) International publication number:
WO 2008/011994 (31.01.2008 Gazette 2008/05)

(54) CAMPTOTHECIN DERIVATIVES WITH ANTITUMOR ACTIVITY

CAMPTOTHECINDERIVATE MIT ANTITUMORWIRKUNG

DÉRIVÉS DE CAMPTOTHÉCINE À ACTIVITÉ ANTITUMORALE

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

(30) Priority: **26.07.2006 IT MI20061473**

(43) Date of publication of application:
08.04.2009 Bulletin 2009/15

(73) Proprietor: **Indena S.p.A.**
20139 Milano (IT)

(72) Inventors:
- **FONTANA, Gabriele**
  I-20139 Milano (IT)
- **BOMBARDELLI, Ezio**
  I-27027 Groppello Cairoli (IT)
- **MANZOTTI, Carla**
  I-20139 Milano (IT)
- **BATTAGLIA, Arturo**
  I-40129 Bologna (IT)
- **SAMORI, Cristian**
  I-47100 Forli (IT)

(74) Representative: **Minoja, Fabrizio**
Bianchetti Bracco Minoja S.r.l.
Via Plinio, 63
20129 Milano (IT)

(56) References cited:
US-A- 5 972 955

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 044 079 B1

Description

[0001] The present invention relates to novel camptothecin derivatives having antitumor activity, the processes for the preparation thereof, the use thereof as antitumor drugs and pharmaceutical compositions containing them.

BACKGROUND OF THE INVENTION

[0002] Camptothecin is an alkaloid extracted from *Camptotheca acuminata* (Nyssaceae), first described by Wall and Wani in 1966 (J. Am. Chem. Soc. 1966, 88, 3888-3890). Camptothecin, albeit endowed with wide spectrum antitumor activity, especially against colon tumor and other solid tumors and leukemias, is not used in therapy due to its high toxicity, which is particularly manifested in the form of hemorrhagic cystitis, gastrointestinal toxicity and myelosuppression.

[0003] A number of camptothecin analogues have been synthesized in order to obtain compounds having low toxicity and high solubility. At present, two drugs are used in clinical practice, namely CPT-11 and topotecan. Other derivatives, such as belotecan, rubitecan, exatecan, gimatecan, pegamotecan, lurtotecan, karenitecin, afeletecan, homocamptothecin, diflomotecan, and many others, are undergoing clinical experimentation. Compound CPT-11 is a highly soluble pro-drug for 10-hydroxy-7-ethylcamptothecin (commonly known as SN-38), approved for the treatment of many solid tumors and ascites (colorectal, skin, stomach, lung, cervice, ovary, non-Hodgkin lymphoma).

[0004] Topotecan is a compound soluble in physiological solution, active against the tumors of the lung, stomach, liver, ovary, breast, prostate, esophagus, rectum, soft tissues sarcomas, head and neck, glioblastoma, chronic and acute myelocytic leukemias. Topotecan shows, however, important side effects such as neutropenia and thrombocytopenia.

[0005] Lurtotecan is a more soluble derivative, having activity in tumors of the neck, ovary, breast, colo-rectal, and pulmonary microcytoma. However, Lurtotecan also has hematic toxicity.

[0006] Rubitecan is a prodrug for the oral use effective against tumors of the pancreas, ovary and breast.

[0007] Camptothecin and its analogues, as is the case with all topoisomerase I inhibitors, are effective against tumors resistant to conventional drugs, including topoisomerase II inhibitors; maintain high topoisomerase levels during the whole cell cycle; do not induce multi-drug resistance (Pgo or MRP) or detoxifying metabolism mediated by the enzyme.

[0008] Research is now focused on novel inhibitors of the topoisomerase I having lower toxicity than the presently used drugs.

[0009] Open-ring camptothecin derivatives show high protein binding (in particular with albumin) and low distribution in the tumor tissues. As a consequence, the product accumulates in the body and tumors are poorly affected.

[0010] Conversely, the high lipophilicity of the lactone form promotes the adhesion of camptothecin derivatives to cell membranes, particularly erythrocytes, affecting the tissue/plasma distribution ratio. For this reason, research is being focused towards two alternative approaches: a) design of low protein binding products still having good solubility; b) design of highly potent products having therapeutical effect even at extremely low doses.

[0011] Modifications at the 7-, 9-, 10- and 11- positions usually proved well tolerated while not affecting the stability of the DNA-Topoisomerase I-camptothecin ternary complex, the formation of which is responsible for the antitumor activity of the compounds.

[0012] Products with 20R configuration proved either inactive or very less active than the products with 20S configuration - which coincides with the natural configuration.

[0013] As a rule, modifications at the 5- position are considered unfavourable to the formation of the ternary complex, whereas modifications at the pyridone rings D and E have been reported to be deleterious to the activity of the product.

[0014] US 5 972 955 discloses camptothecin derivatives having anti-tumor activity characterized by keto oxygen atom on the D-ring.

DISCLOSURE OF THE INVENTION

[0015] In a first aspect, the invention relates to camptothecin derivatives of general formula I:



(I)

wherein:

R is F, Cl, Br, I, -N3, NH2, -NR'R", -COOR', -CONR'R", -NHR"'-NR'R" in which R', R" and R"' can be H, alkyl, aryl, arylalkyl, acyl, alkoxycarbonyl, aryloxycarbonyl;
R1 is alkyl, aminoalkyl, hydroxyalkyl, nitrile, -NH-O-alkyl -NH-O-aryl, silylalkyl;
R2 is hydrogen, hydroxyl, alkoxy, aminoalkyl;
R3 is hydrogen, alkoxy, aminoalkyl,
wherein the alkyl, acyl, alkoxy, aminoalkyl or -NH-O-alkyl, groups can contain 1 to 8, preferably 1 to 4, carbon atoms, in a straight or branched chain, and the aryl and aryloxy groups can contain 5 to 10 carbon atoms;
the pharmaceutically acceptable salts, isomers, enantiomers, diastereomers thereof and corresponding mixtures.

[0016] The compounds of the invention show low protein binding and have good solubility and high potency even at very low doses.

[0017] The preferred synthetic route for the preparation of the compounds of the invention is illustrated in Scheme I wherein:

a) protection of the precursor hydroxy groups;
b) conversion of the pyridone ring to thiopyridone ring;
c) removal of the protective groups.

Scheme I



[0018] In Scheme I, R, R1, R2 and R3 have the meanings described above, and PG is a hydroxy-protecting group.

[0019] Precursors may be commercially available or obtained as described in the literature. For the preparation of the products derivatized at the 5-position, the approach described in Scheme II can be followed, which comprises:

a) protection of the precursor hydroxy groups;
b) derivatization at 5 through formation of a carbanion and reaction with an electrophilic reagent;
c) transformation of the 16a carbonyl into thiocarbonyl;
d) deprotection of the hydroxy groups;
in which steps b) and c) can be reversed.

Scheme II



[0020] In Scheme II, R, R1, R2 and R3 have the meanings described above, and PG is an OH-protecting group.

[0021] The formation of the carbanion at 5 can be obtained treating the precursor with a strong organic base, preferably LiHMDS.

[0022] The carbanion is reacted *in situ* with an electrophile, such as a source of halogen, an azadicarboxylate, isocyanate, chlorocarbonyl derivative, tosylazide.

[0023] Conversion of the pyridone ring to thiopyridone ring can be obtained by reaction with 2,4-bis(4-methoxyphenyl)-1,2,3,4-dithiaphosphethane-2,4-disulfide (commonly known as Lawesson's reagent) (Cava P.M. et al., Tetrahedron 1985, 41, 5061; Cherkasov RA et al Tetrahedron 1985 41, 2567; Ghattas AAG et al, Sulfur Lett. 1982, 1, 69; Yde B et al, Tetrahedron 1984, 40. 2047) or with an equivalent reagent. Lawesson's reagent is preferred.

[0024] Silyls and carbamates or a combination thereof are preferred as hydroxy-protecting groups.

[0025] The compounds of the invention were tested in a cytotoxicity assay on a wide spectrum of tumour cells. By way of example, the cytotoxicity data on the NCI-H460 cell line (NSCL cancer) concerning two compounds of formula (I) are reported, using camptothecin and the drugs Topotecan and SN-38 as references:

Name	Formula	NCI-H460 IC50 (μg/mL) Cell count
Camptothecin	 MW =348.36 C20H16N2O4	0.115 ± 0.0174

(continued)

Name	Formula	NCI-H460 IC50 (μg/mL) Cell count
Topotecan	 MW = 421 C23H23N3O5	0.63 ± 0.44
SN38	 MW =392.42 C22H20N2O5	0.0865 ± 0.0049
IDN 6070 *thiocamptothecin*	 MW = 364 C20H16N2O3S	0.05 ± 0.021
IDN 6092	 MW = 405.44 C20H15N5O3S	0.3 ± 0.07
IDN 6093	 MW = 405.44 C20H15N5O3S	0.72 ± 0.2
IDN 6156 Thio-SN38	 MW =408.48 C22H20N2O4S	0.0095 ± 0.0007
IDN 6180 Thio-topotecan	 MW: 437.52 C23H23N3O4S	0.115 ± 0.021

(continued)

Name	Formula	NCI-H460 IC50 (μg/mL) Cell count
IDN 6181 10-hydroxy-thiocamptothecin	 MW = 380,43 $C_{20}H_{16}N_2O_4S$	0.035 ± 0.011

[0026] Cytotoxicity tests showed that camptothecin sulforated derivatives are on the average 10 times more potent than non-sulforated analogues.

[0027] The most active compounds were evaluated in a DNA cleavage assay measuring the active concentration and damage persistence (see the section 'Examples'). The derivatives of formula (I) surprisingly show higher persistence in blocking DNA replication than the reference standards (particularly topotecan and camptothecin), while maintaining an effective cytotoxic activity.

[0028] Moreover, sulforated derivatives proved more active than non-sulforated analogues also in this case, as they induced DNA damage at lower concentrations and with longer persistence on time.

[0029] Compound thio-SN38 (IDN6156) was transformed into thio-CPT11 (thio-Irinotecan) according to procedures for the conversion of SN38 to CPT11 (Irinotecan) reported in the literature. The resulting compound thio-irinotecan was compared *in vivo* with close non-sulforated analogue in clinical use (CPT11) on a lung tumor model highly sensitive to the standard references.

[0030] The data reported in the following table show that the sulforated compound thio-CPT11 is more potent than non non-sulforated analogue CPT11, while keeping the same effectiveness level with better tolerability and therapeutic index.

Drug[a]	Dose (mg/kg/inj.)	TWI%[b]	LCK[c] (0.5 g)	Max[d] BWL%	Tox/Tot[e]
CPT 11	50	91	1.8	15	0/5
Tio-CPT11	10	94	2.3	9	0/5

[0031] In a further aspect, the invention relates to pharmaceutical compositions containing a compound of formula (I) together with pharmaceutically acceptable carriers and excipients. The pharmaceutical forms suitable to the oral or parenteral administration of the compounds (I) can be solid, preferably capsules, tablets and granules, or liquid, preferably injectable or infusion solutions.

[0032] The suitably formulated compounds of the invention can be used for the treatment of solid tumors and leukemias, in particular tumors of the lung, ovary, breast, stomach, liver, prostate, soft tissue sarcomas, head and neck, esophagus, pancreas, colon, rectum, glioblastoma, chronic and acute myelocytic leukemias.

EXAMPLES

EXAMPLE I - 20-OTES-camptothecin

[0033] Camptothecin (0.100 g, 0.287 mmols) is suspended in anhydrous dimethylformamide (3 mL), under inert atmosphere, and the resulting suspension is added with imidazole (0.980 g, 1.44 mmols). The mixture is stirred for 10' minutes, subsequently triethylsilyl chloride (TES-Cl) (0.193 mL, 1.15 mmols) is dropped therein, followed by addition of 4-dimethylamino pyridine (DMAP) (0.040 g 0.287 mmols). After 46 h, the reaction mixture is evaporated under vacuum, (TLC control of the complete disappearance of the reagent, eluent CH_2Cl_2/MeOH = 30/1). The solid is subsequently redissolved in CH_2Cl_2 and washed with H_2O and saturated NH_4Cl. The aqueous phase is extracted with CH_2Cl_2 (2 X 10 mL). The organic phases are combined and dried over Na_2SO_4, filtered and concentrated under vacuum, thereby obtaining the desired product (0.133 g, 0.287 mmols) as a pale yellow solid.

[0034] ^1H NMR ($CDCl_3$, 400 MHz) δ 8.37 (s, 1H, Ar, H-7), 8.25 (d, 1H, *J* = 8.4 Hz, Ar), 7.92 (d, 1 H, *J* = 8.0 Hz, Ar), 7.82 (t, 1 H, *J* = 8.0 Hz, Ar), 7.65 (t, 1 H, *J* = 8.4 Hz, Ar), 7.57 (s, 1 H, H-14), 5.67 (d, 1H, *J* = 16.4 Hz, H-17), 5.29 (s, 2H, H-5), 5.25 (d, 1H, *J* = 16.4 Hz, H-17), 2.00-1.84 (m, 2H, H-19), 1.03-0.93 (m, 12 H), 0.80-0.71 (m, 6 H). ^{13}C NMR ($CDCl_3$, 100 MHz) δ 171.7, 157.6, 152.5, 151.5, 149.0. 145.9, 130.9, 130.4, 130.0. 128.4, 128.1, 128.0. 127.9, 118.9, 94.4, 75.3, 66.0. 50.0. 33.2, 7.9, 7.2, 6.4.

EXAMPLE II - 20-OTES-Thio-camptothecin

[0035] Camptothecin 20-OTES (0.664 g, 1.44 mmols), is dissolved in anhydrous xylene (20 mL) with stirring under inert atmosphere. Subsequently Lawesson's reagent (LR), (0.523 g, 1.29 mmols) is added and the reaction is heated to 90°C. The reaction mixture is reacted for 18 h at 90°C, monitoring by TLC the disappearance of the reagent (Hexane/AcOEt = 1/1). The solvent is evaporated off under vacuum and the residue is purified by flash chromatography (SiO_2, Hexane/AcOEt = 4/1 then 7/2), thereby obtaining the desired product (0.578 g, 1.21 mmol, 84%) as an intense yellow solid.

[0036] ^{1}H NMR ($CDCl_3$, 400 MHz) δ 8.46 (s, 1 H, Ar, H-7) 8.29 (d, 1 H, J = 8.4 Hz, Ar), 8.03 (s, 1H, H-14), 7.97 (d, 1H, J = 8.4 Hz, Ar), 7.86 (t, 1H, J = 21.8 Hz, Ar), 7.69 (t, 1 H, J = 8.4 Hz, Ar), 6.15 (d, 1 H, J = 16.9 Hz, H-17), 5.62 (d, 1 H, J = 21.0 Hz, H-5), 5.57 (d, 1 H, J = 21.0 Hz, H-5), 5.34 (d, 1 H, J = 16.9 Hz, H-17), 1.94 (d, 1H, J = 7.6 Hz, H-19), 1.90 (d, 1H, J = 7.6 Hz, H-19), 1.05-0.91 (m, 12 H), 0.82-0.71 (m, 6 H). ^{13}C NMR ($CDCl_3$, 100 MHz) δ 172.3, 171.5, 151.9, 149.1, 148.3, 147.2, 130.8, 130.6, 130.6, 130.1, 128.3, 128.2, 128.2, 128.0. 104.5, 75.0. 68.8, 56.3, 33.5, 7.7, 7.2, 6.4.

EXAMPLE III - Preparation of Thio-camptothecin (IDN 6070)

[0037] 20-OTES Thio-camptothecin (0.150 g, 0.314 mmols) is dissolved in anhydrous THF (10 mL) with stirring under inert atmosphere, subsequently Et_3N•3HF (0.140 mL, 0.816 mmols) is dropped therein. The reaction mixture is reacted for 48 h at room temperature, monitoring by TLC the disappearance of the reagent (Hexane/AcOEt = 1/1). The solvent is evaporated off under vacuum and the residue is purified by flash chromatography (SiO_2, Hexane/AcOEt = 2/1 then 1/1), thereby obtaining the desired product (0.112 g, 0.307 mmol, 98%) as an intense yellow solid.

[0038] ^{1}H NMR ($CDCl_3$, 400 MHz) δ 8.46 (s, 1H, Ar, H-7), 8.27 (d, 1H, J = 8.4 Hz, Ar), 8.13 (s, 1H, H-14), 7.97 (d, 1H, J = 8.4 Hz, Ar), 7.86 (t, 1H, J = 21.8 Hz, Ar), 7.70 (t, 1 H, J = 8.4 Hz, Ar), 6.25 (d, 1H, J = 16.9 Hz, H-17), 5.62 (d, 1 H, J = 21.0 Hz, H-5), 5.58 (d, 1 H, J = 21.0 Hz, H-5), 5.37 (d, 1 H, J = 16.9 Hz, H-17), 3.80 (s, 1 H, OH), 1.90 (q, 2H, H-19), 1.03 (t, 3 H, J = 7.2 Hz, Me). ^{13}C NMR ($CDCl_3$, 100 MHz) δ 173.5, 172.6, 151.8, 149.1, 148.7, 145.5, 130.9, 130.8, 130.5, 129.9, 128.3 (2 C), 128.2, 128.0. 104.3, 72.3, 69.2, 56.3, 32.0. 7.8.

EXAMPLE IV - 20-OTES SN-38

[0039] SN-38 (0.100 g, 0.255 mmols) is suspended in anhydrous dimethylformamide (5 mL), under inert atmosphere and the resulting suspension is added with imidazole (0.087 g, 1.28 mmols). The mixture is stirred for 10' minutes, subsequently triethylsilyl chloride (TES-Cl), (0.171 mL, 1.02 mmols) is dropped therein, followed by addition of 4-dimethylamino pyridine (DMAP) (0.031 g, 0.255 mmols). After 52 h, the reaction mixture is evaporated under vacuum, monitoring by TLC (CH_2Cl_2/MeOH = 10/1) the complete disappearance of the reagent. The solid is subsequently redissolved in CH_2Cl_2 and washed with H_2O and saturated NH_4Cl. The aqueous phase is extracted with CH_2Cl_2 (2 X 10 mL). The organic phases are combined and dried over Na_2SO_4, filtered and concentrated under vacuum, thereby obtaining the desired product (0.121 g, 0.240 mmol, 94%) as a pale yellow solid.

[0040] ^{1}H NMR ($CDCl_3$, 400 MHz) δ 9.26 (br s, 1 H,OH), 8.14 (d, 1 H, J = 9.2 Hz, Ar, H-12), 7.58 (s, 1 H, H-14), 7.49 (dd, 1H, J_1 = 9.2 Hz J_2 = 2.2 Hz, H-11), 7.46 (d, 1H, J = 2.2 Hz, H-9), 5.70 (d, 1 H, J = 16.5 Hz, H-17), 5.28 (d, 1 H, J = 16.5 Hz, H-17), 5.23 (s, 2H, H-5), 3.05 (q, 2H, J = 7.5 Hz), 1.97-1.81 (m, 2H, H-19), 1.32 (t, 3 H, J = 7.5 Hz, Me), 0.98-0.88 (m, 12 H), 0.77-0.68 (m, 6 H). ^{13}C NMR ($CDCl_3$, 100 MHz) δ 172.1, 157.9, 156.6, 152.1, 149.0. 146.7, 144.6, 143.6, 131.9, 128.7, 126.9, 122.8, 117.9, 105.5, 98.5, 75.4, 65.9, 49.5, 32.9, 23.2, 13.5, 7.8, 7.2, 6.4.

EXAMPLE V - 10-OTBDMS-20-OTES SN-38

[0041] 20-OTES SN-38 (0.121 g, 0.240 mmols) is dissolved in a CH_2Cl_2/THF = 1:1 (8 mL) anhydrous mixture under inert atmosphere. Imidazole (0.081 g, 1.20 mmols) is added thereto followed, after 10' minutes, by tert-butyldimethylsilyl chloride (TBDMS-Cl), (0.144 mg, 0.957 mmols), then by 4-dimethylamino pyridine (DMAP), (0.029 g 0.240 mmols). After 18 h, the reaction mixture is evaporated under vacuum, monitoring by TLC (Hexane/AcOEt = 1/1) the disappearance of the reagent. The solid is subsequently redissolved in CH_2Cl_2 and washed with H_2O and saturated NH_4Cl. The aqueous phase is extracted with CH_2Cl_2 (2 X 10 mL) and the organic phases are combined, dried over Na_2SO_4, filtered and concentrated under vacuum. The residue is purified by flash chromatography (SiO_2, Hexane/AcOEt = 1/1), thereby obtaining the desired product (0.127 g, 0.205 mmol, 85%) as a pale yellow solid.

[0042] ^{1}H NMR ($CDCl_3$, 400 MHz) δ 8.14 (d, 1H, J = 8.8 Hz, Ar, H-12), 7.49 (s, 1 H, H-14), 7.40 (d, 1 H, J = 2.2 Hz, H-9), 7.38 (dd, 1 H, J_1 = 8.8 Hz J_2 = 2.5 Hz, H-11), 5.67 (d, 1 H, J = 16.5 Hz, H-17), 5.25 (d, 1 H, J = 16.5 Hz, H-17), 5.23 (s, 2H, H-5), 3.11 (q, 2H, J = 7.6 Hz), 1.99-1.82 (m, 2H, H-19), 1.38 (t, 3 H, J = 7.6 Hz, Me), 1.04 (s, 9 H), 1.00-0.92 (m, 12 H), 0.78-0.69 (m, 6 H), 0.30 (s, 6 H). ^{13}C NMR ($CDCl_3$, 100 MHz) δ 171.9, 157.7, 155.1, 151.5, 150.1, 146.8,

145.6, 143.5, 132.2, 128.2, 126.9, 125.9, 118.0. 110.5, 97.7, 75.4, 66.0. 49.3, 33.2, 25.6, 23.1, 18.3, 13.7, 7.9, 7.2, 6.4, -4.3.

EXAMPLE VI - 10-OTBDMS 20-OTES ThioSN-38

[0043] SN-38 10-OTBDMS 20-OTES (0.127 g, 0.205 mmols) is dissolved in anhydrous xylene (6 mL) with stirring under inert atmosphere. Subsequently Lawesson's reagent (LR), (0.075 g, 0.184 mmols) is added and the reaction is heated to 90°C. The reaction mixture is reacted for 23 h at 90°C, monitoring by TLC (Hexane/AcOEt = 2/1) the disappearance of the reagent. The solvent is evaporated off under vacuum and the residue is purified by flash chromatography (SiO_2, Hexane/AcOEt = 5/1), thereby obtaining the desired product (0.042 g, 0.066 mmol, 32%) as an intense yellow solid.

[0044] ^{1}H NMR ($CDCl_3$, 400 MHz) δ 8.17 (d, 1H, *J* = 8.9 Hz, Ar, H-12), 7.96 (s, 1 H, H-14), 7.43 (d, 1 H, *J* = 2.6 Hz, H-9), 7.41 (dd, 1 H, J_1 = 8.8 Hz J_2 = 2.6 Hz, H-11), 6.16 (d, 1H, *J* = 17.1 Hz, H-17), 5.56 (d, 1H, *J* = 20.0 Hz, H-5), 5.50 (d, 1H, *J* = 20.0 Hz, H-5), 5.33 (d, 1 H, *J* = 16.5 Hz, H-17), 3.18 (q, 2H, *J* = 7.6 Hz), 1.91 (q, 2H, *J* = 7.4 Hz, H-19), 1.41 (t, 3 H, *J* = 7.6 Hz, Me), 1.05 (s, 9 H), 1.03-0.92 (m, 12 H), 0.81-0.72 (m, 6 H), 0.31 (s, 6 H). ^{13}C NMR ($CDCl_3$, 100 MHz) δ 172.1, 171.5, 155.4, 149.4, 149.3, 147.4, 145.7, 143.6, 132.4, 129.9, 128.5, 126.5, 126.2, 110.5, 104.1, 75.0. 68.8, 55.8, 33.5, 25.7, 23.2, 18.4, 13.9, 7.8, 7.2, 6.5, -4.3.

EXAMPLE VII - 20-OTES ThioSN-38

[0045] 10-OTBDMS 20-OTES ThioSN-38 (0.042 g, 0.066 mmols) is dissolved in anhydrous THF (4 mL) with stirring under inert atmosphere, subsequently Et3N•3HF (0.013 mL, 0.080 mmols) is dropped therein. The reaction mixture is reacted for 3 h at room temperature, monitoring by TLC the disappearance of the reagent (Hexane/AcOEt = 2/1). The solvent is evaporated off under vacuum and the residue is purified by flash chromatography (SiO_2, Hexane/AcOEt = 2/1 then 1/1), thereby obtaining the desired product (0.034 g, 0.065 mmol, 99%) as an intense yellow solid.

[0046] ^{1}H NMR ($CDCl_3$, 400 MHz) δ 8.19 (d, 1 H, *J* = 9.2 Hz, Ar, H-12), 7.96 (s, 1 H, H-14), 7.44 (dd, 1 H, J_1 = 8.8 Hz J_2 = 2.6 Hz, H-11), 7.43 (d, 1 H, *J* = 2.6 Hz, H-9), 6.16 (d, 1H, *J* = 17.1 Hz, H-17), 6.02 (br s, 1H, OH), 5.55 (d, 1H, *J* = 19.7 Hz, H-5), 5.49 (d, 1 H, *J* = 19.7 Hz, H-5), 5.33 (d, 1 H, *J* = 16.9 Hz, H-17), 3.16 (q, 2H, *J* = 7.8 Hz), 1.91 (q, 2H, *J* = 7.6 Hz, H-19), 1.39 (t, 3 H, *J* = 7.9 Hz, Me), 1.03-0.92 (m, 12 H), 0.81-0.72 (m, 6 H). ^{13}C NMR ($CDCl_3$, 100 MHz) δ 172.0. 171.7, 155.6, 149.1, 149.0. 147.3, 145.2, 143.7, 132.5, 130.0. 128.7, 126.7, 122.4, 105.5, 104.2, 75.1, 68.9, 55.8, 33.5, 23.1, 13.7, 7.7, 7.2, 6.4.

EXAMPLE VIII - ThioSN-38 (IDN 6156)

[0047] 20-OTES ThioSN-38 (0.034 g, 0.065 mmols) is dissolved in anhydrous THF (4 mL) with stirring under inert atmosphere, subsequently Et3N•3HF (0.025 mL, 0.150 mmols) is dropped therein. The reaction mixture is reacted for 40 h at room temperature, monitoring by TLC the disappearance of the reagent (Hexane/AcOEt = 1/1). The solvent is evaporated off under vacuum and the residue is purified by flash chromatography (SiO_2, Hexane/AcOEt = 1/3), thereby obtaining the desired product (0.026 g, 0.064 mmol, 98%) as an intense yellow solid.

[0048] ^{1}H NMR (THF-d_8, 400 MHz) δ 9.23 (br s, 1 H, OH), 8.06 (d, 1 H, *J* = 9.2 Hz, Ar, H-12), 7.88 (s, 1 H, H-14), 7.41 (d, 1 H, *J* = 2.8 Hz, H-9), 7.38 (dd, 1 H, J_1 = 9.2 Hz J_2 = 2.8 Hz, H-11), 6.08 (d, 1H, *J* = 17.2 Hz, H-17), 5.67 (br s, 1H, OH), 5.50 (s, 2H, H-5), 5.33 (d, 1 H, *J* = 16.8 Hz, H-17), 3.22 (q, 2H, *J* = 7.8 Hz), 1.90 (q, 2H, *J* = 7.6 Hz, H-19), 1.42 (t, 3 H, *J* = 7.6 Hz, Me), 0.97 (t, 3 H, *J* = 7.6 Hz, Me). ^{13}C NMR (THF-d_8, 100 MHz) δ 173.0. 172.1, 157.5, 149.6, 149.2, 146.1, 145.0. 142.6, 132.3, 130.1, 128.9, 127.6, 122.3, 104.9, 102.3, 72.3, 68.5, 55.8, 31.7, 22.7, 13.1, 7.3.

EXAMPLE IX - 20-OTES Topotecan

[0049] Topotecan (0.100 g, 0.238 mmols) is suspended in anhydrous dimethylformamide (5 mL), under inert atmosphere and the resulting suspension is added with imidazole (0.081 g, 1.19 mmols). The mixture is stirred for 10' minutes, subsequently triethyl silyl chloride (TES-Cl), (0.160 mL, 0.952 mmols) is dropped therein, followed by addition of 4-dimethylaminopyridine, (DMAP), (0.029 g 0.238 mmols). After 52 h, the reaction mixture is evaporated under vacuum, monitoring by TLC (CH_2Cl_2/MeOH = 10/1) the complete disappearance of the reagent. The solid is subsequently redissolved in $CHCl_3$ and H_2O and saturated NH_4Cl, the aqueous phase is extracted with $CHCl_3$ (2 X 15 mL). The organic phases are combined and dried over Na_2SO_4, filtered and concentrated under vacuum, thereby obtaining the desired product (0.120 g, 0.224 mmol, 94%) as a pale yellow solid.

[0050] ^{1}H NMR ($CDCl_3$, 400 MHz) δ 9.65 (br s, 1 H), 8.26 (s, 1 H, Ar, H-7), 8.14 (d, 1 H, *J* = 8.8 Hz, Ar, H-12), 7.80 (d, 1 H, *J* = 8.8 Hz, Ar, H-11), 7.58 (s, 1 H, H-14), 5.67 (d, 1 H, *J* = 16.5 Hz, H-17), 5.25 (d, 1 H, *J* = 16.5 Hz, H-17), 5.20 (s, 2H, H-5), 4.71 (s, 2 H), 2.81 (s, 6H, 2 Me), 1.97-1.81 (m, 2H, H-19), 0.98-0.88 (m, 12 H), 0.77-0.68 (m, 6 H). ^{13}C NMR ($CDCl_3$, 100 MHz) δ 172.1, 157.9, 156.6, 152.1, 150.8, 146.8, 144.3, 134.3, 131.2 129.9, 127.9, 123.0. 118.9, 110.1, 98.5, 75.4, 65.9, 51.1, 50.0. 43.1, 32.9, 7.8, 7.2, 6.4.

EXAMPLE X - 10-OTBDMS 20-OTES Topotecan

[0051] 20-OTES Topotecan (0.120 g, 0.224 mmmols) is dissolved in a CH_2Cl_2/THF = 1:1 anhydrous mixture (8 mL) under inert atmosphere. Imidazole (0.076 g, 1,12 mmols) is added followed, after 10' minutes, by tert-butyldimethylsilyl chloride (TBDMS-Cl), (0.135 mg, 0.896 mmols), then by 4-dimethylamino pyridine (DMAP), (0.027 g 0.224 mmols). After 21 h, the reaction mixture is evaporated under vacuum, monitoring by TLC (Hexane/AcOEt = 1/1) the disappearance of the reagent. The solid is subsequently redissolved in $CHCl_3$ and H_2O and saturated NH_4Cl, the aqueous phase is extracted with $CHCl_3$ (2 X 15 mL). The organic phases are combined and dried over Na_2SO_4, filtered and concentrated under vacuum. The residue is purified by flash chromatography (SiO_2, Hexane/AcOEt = 1/1), thereby obtaining the desired product (0.116 g, 0.179 mmol, 80%) as a pale yellow solid.

[0052] ^1H NMR ($CDCl_3$, 400 MHz) δ 8.26 (s, 1H, Ar, H-7), 8.14 (d, 1H, *J* = 8.8 Hz, Ar, H-12), 7.81 (d, 1H, *J* = 8.8 Hz, Ar, H-11), 7.59 (s, 1H, H-14), 5.64 (d, 1H, *J* = 16.5 Hz, H-17), 5.22 (d, 1H, *J* = 16.5 Hz, H-17), 5.19 (s, 2H, H-5), 4.71 (s, 2 H), 2.81 (s, 6H, 2 Me), 1.97-1.81 (m, 2H, H-19), 1.04 (s, 9 H), 0.98-0.88 (m, 12 H), 0.77-0.68 (m, 6 H), 0.30 (s, 6 H). ^{13}C NMR ($CDCl_3$, 100 MHz) δ 171.7, 157.7, 155.1, 151.5, 150.0. 146.8, 144.3, 134.3, 131.2 129.9, 127.9, 123.0. 118.9, 110.1, 98.5, 75.4, 65.9, 51.1, 50.0. 43.9, 32.9, 25.6, 18.3, 7.8, 7.2, 6.4, -4.3.

EXAMPLE XI - 10-OTBDMS 20-OTES Thio-Topotecan

[0053] 10-OTBDMS 20-OTES Topotecan (0.116 g, 0.179 mmmols) is dissolved in anhydrous xylene (6 mL) with stirring, under inert atmosphere. Subsequently Lawesson's reagent (LR), (0.065 g, 0.161 mmols) is added and the reaction is heated to 90°C. The reaction mixture is reacted for 23 h at 90°C, monitoring by TLC (Hexane/AcOEt = 2/1) the disappearance of the reagent. The solvent is evaporated off under vacuum and the residue is purified by flash chromatography (SiO_2, Hexane/AcOEt = 5/1), thereby obtaining the desired product (0.047 g, 0.072 mmol, 40%) as an intense yellow solid.

[0054] ^1H NMR ($CDCl_3$, 400 MHz) δ 8.35 (s, 1 H, Ar, H-7), 8.17 (d, 1 H, *J* = 8.8 Hz, Ar, H-12), 7.96 (s, 1H, H-14), 7.85 (d, 1H, *J* = 8.8 Hz, Ar, H-11), 6.16 (d, 1H, *J* = 16.5 Hz, H-17), 5.52 (d, 1 H, *J* = 21.0 Hz, H-5), 5.48 (d, 1 H, *J* = 21.0 Hz, H-5), 5.33 (d, 1H, *J* = 16.5 Hz, H-17), 4.73 (s, 2 H), 2.81 (s, 6H, 2 Me), 1.92 (q, 2H, *J* = 7.6 Hz, H-19), 1.04 (s, 9 H), 0.98-0.88 (m, 12 H), 0.77-0.68 (m, 6 H), 0.30 (s, 6 H). ^{13}C NMR ($CDCl_3$, 100 MHz) δ 172.5, 171.5, 155.1, 149.9, 149.4, 147.2, 144.3, 134.3, 132.1 129.9, 127.9, 126.5, 123.0. 110.1, 104.2, 75.4, 67.9, 55.1, 50.0. 43.9, 32.9, 25.6, 18.3, 7.8, 7.2, 6.4, -4.3.

EXAMPLE XII - 20-OTES Thio-Topotecan

[0055] 10-OTBDMS 20-OTES Thio-Topotecan (0.047 g, 0.072 mmols) is dissolved in anhydrous THF (4 mL) with stirring under inert atmosphere, subsequently Et3N•3HF (0.014 mL, 0.086 mmols) is dropped therein. The reaction mixture is reacted for 4 h at room temperature, monitoring by TLC the disappearance of the reagent (Hexane/AcOEt = 2/1). The solvent is evaporated off under vacuum and the residue is purified by flash chromatography (SiO_2, Hexane/AcOEt = 2/1 then 1/1), thereby obtaining the desired product (0.039 g, 0.071 mmol, 99%) as an intense yellow solid.

[0056] ^1H NMR ($CDCl_3$, 400 MHz) δ 8.36 (s, 1 H, Ar, H-7), 8.17 (d, 1 H, *J* = 8.8 Hz, Ar, H-12), 7.96 (s, 1H, H-14), 7.85 (d, 1H, *J* = 8.8 Hz, Ar, H-11), 6.16 (d, 1H, *J* = 16.5 Hz, H-17), 6.02 (br s, 1 H, OH), 5.52 (d, 1 H, *J* = 21.0 Hz, H-5), 5.48 (d, 1 H, *J* = 21.0 Hz, H-5), 5.33 (d, 1H, *J* = 16.5 Hz, H-17), 4.73 (s, 2 H), 2.81 (s, 6H, 2 Me), 1.92 (q, 2H, *J* = 7.2 Hz, H-19), 0.98-0.88 (m, 12 H), 0.77-0.68 (m, 6 H). ^{13}C NMR ($CDCl_3$, 100 MHz) δ 172.5, 171.5, 155.1, 149.9, 149.4, 147.2, 144.3, 134.3, 132.1 129.9, 127.9, 126.5, 123.0. 110.1, 104.2, 75.4, 67.9, 55.1, 50.0. 43.9, 32.9, 7.8, 7.2, 6.4.

EXAMPLE XIII - Thio-Topotecan (IDN 6180)

[0057] Thio-Topotecan 10-OH 20-OTES (0.039 g, 0.071 mmols) is dissolved in anhydrous THF (4 mL) with stirring under inert atmosphere, subsequently Et3N•3HF (0.026 mL, 0.163 mmols) is dropped therein. The reaction mixture is reacted for 40 h at room temperature, monitoring by TLC the disappearance of the reagent (Hexane/AcOEt = 1/2). The solvent is evaporated off under vacuum and the residue is purified by flash chromatography (SiO_2, Hexane/AcOEt = 1/3), thereby obtaining the desired product (0.030 g, 0.069 mmol, 98%) as an intense yellow solid.

[0058] ^1H NMR ($CDCl_3$, 400 MHz) δ 8.36 (s, 1H, Ar, H-7), 8.17 (d, 1 H, *J* = 8.8 Hz, Ar, H-12), 7.96 (s, 1H, H-14), 7.85 (d, 1H, *J* = 8.8 Hz, Ar, H-11), 6.16 (d, 1H, *J* = 16.5 Hz, H-17), 6.02 (br s, 1 H, OH), 5.52 (d, 1 H, *J* = 21.0 Hz, H-5), 5.48 (d, 1 H, *J* = 21.0 Hz, H-5), 5.33 (d, 1 H, *J* = 16.5 Hz, H-17), 4.73 (s, 2 H), 3.84 (br s, 1 H, OH), 2.81 (s, 6H, 2 Me), 1.92 (q, 2H, *J* = 7.6, Hz H-19), 1.03 (t, 3 H, *J* = 7.6 Hz, Me). ^{13}C NMR ($CDCl_3$, 100 MHz) δ 172.5, 171.5, 155.1, 149.9, 149.4, 147.2, 144.3, 134.3, 132.1 129.9, 127.9, 126.5, 123.0. 110.1, 104.2, 72.4, 67.9, 55.1, 50.0. 43.9, 32.9, 7.8.

EXAMPLE XIV - Preparation of 20-OTES 10-hydroxycamptothecin

[0059] 10-Hydroxycamptothecin (0.100 g, 0.275 mmols) is suspended in anhydrous dimethylformamide (5 mL), under inert atmosphere and the resulting suspension is added with imidazole (0.225 g, 3.31 mmols). The mixture is stirred for 10' minutes, subsequently triethylsilyl chloride (TES-Cl), (0.460 mL, 2,75 mmols) is dropped therein, followed by addition of 4-dimethylamino pyridine (DMAP) (0.068 g, 0.550 mmols). After 24 h the reaction mixture is evaporated under vacuum, monitoring by TLC the complete disappearance of the reagent (CH_2Cl_2/MeOH = 20/1). The solid is subsequently redissolved in CH_2Cl_2 and washed with H_2O and saturated NH_4Cl. The aqueous phase is extracted with CH_2Cl_2 (2 X 10 mL). The organic phases are combined, dried over Na_2SO_4, filtered and concentrated under vacuum, thereby obtaining the desired product (0.124 g, 0.259 mmol, 94%) as a pale yellow solid.

[0060] ^{1}H NMR ($CDCl_3$ + 5% CD_3OD, 400 MHz) δ 8.10 (s, 1H, Ar, H-7), 8.05 (d, 1H, J = 9.2 Hz, Ar), 7.50 (s, 1 H, H-14), 7.39 (dd, 1 H, J_1 = 9.2 Hz J_2 = 2.4 Hz, H-11), 7.11 (d, 1H, J = 2.2 Hz, H-9), 5.60 (d, 1 H, J = 16.4 Hz, H-17), 5.21 (d, 1H, J = 16.4 Hz, H-17), 5.15 (s, 2H, H-5), 1.97-1.81 (m, 2H, H-19), 0.98-0.88 (m, 12 H), 0.76-0.68 (m, 6 H). ^{13}C NMR ($CDCl_3$ + 5% CD_3OD, 100 MHz) δ 172.2, 157.8, 156.7, 151.8, 149.2, 146.1, 144.1, 130.9, 129.8, 129.0, 128.6, 123.2, 117.8, 108.8, 98.1, 75.4, 65.8, 50.0. 32.9, 7.7, 7.1, 6.3.

EXAMPLE XV - 10-OTBDMS-20-OTES Camptothecin

[0061] 10-Hydroxy-20-OTES-Camptothecin (0.105 g, 0.219 mmols) is dissolved in a CH_2Cl_2/THF = 1:1 anhydrous mixture (4 mL) and under inert atmosphere. Imidazole (0.097 g, 1.42 mmols) is added followed, after 10' minutes, by tert-butyldimethylsilyl chloride (TBDMS-Cl), (0.164 mg, 1.10 mmols), then by 4-dimethylamino pyridine (DMAP) (0.040 g, 0.329 mmols). After 18 h, the reaction mixture is evaporated under vacuum, monitoring by TLC the complete disappearance of the reagent (Ciclohexane/AcOEt = 1/3). The solid is subsequently redissolved in CH_2Cl_2 and washed with H_2O and saturated NH_4Cl, the aqueous phase is extracted with CH_2Cl_2 (2 X 10 mL). The organic phases are combined, dried over Na_2SO_4, filtered and concentrated under vacuum. The residue is purified by flash chromatography (SiO_2, Ciclohexane/AcOEt = 1/3), thereby obtaining the desired product (0.117 g, 0.197 mmol, 90%) as a pale yellow solid.

[0062] ^{1}H NMR ($CDCl_3$, 400 MHz) δ 8.22 (s, 1 H, Ar, H-7), 8.13 (d, 1 H, J = 9.2 Hz, Ar, H-12), 7.51 (s, 1H, H-14), 7.39 (dd, 1H, J_1 = 9.2 Hz J_2 = 2.8 Hz, H-11), 7.22 (d, 1 H, J = 2.8 Hz, H-9), 5.66 (d, 1 H, J = 16.5 Hz, H-17), 5.25 (s, 2H, H-5), 5.24 (d, 1 H, J = 16.5 Hz, H-17), 1.99-1.82 (m, 2H, H-19), 1.03 (s, 9 H), 1.00-0.92 (m, 12 H), 0.78-0.69 (m, 6 H), 0.29 (s, 6 H). ^{13}C NMR ($CDCl_3$, 100 MHz) δ 172.0. 157.7, 155.1, 151.5, 150.6, 146.1, 145.1, 131.4, 129.4, 129.3, 128.7, 126.7, 118.3, 114.5, 97.7, 75.3, 66.0. 49.9, 33.1, 25.6, 18.3, 7.9, 7.2, 6.4, -4.3.

EXAMPLE XVI - 10-OTBDMS-20-OTES Thio-Camptothecin

[0063] 10-OTBDMS 20-OTES Camptothecin (0.350 g, 0.589 mmols) is dissolved in anhydrous xylene (10 mL) with stirring under inert atmosphere. Subsequently Lawesson's reagent (LR), (0.590 g, 1,47 mmols) is added and the reaction is heated to 90°C. The reaction mixture is reacted for 18 h a 95°C, monitoring by TLC the disappearance of the reagent (Ciclohexane/AcOEt = 1/1). The solvent is evaporated off under vacuum and the residue is purified by flash chromatography (SiO_2, Ciclohexane/AcOEt = 4/1), thereby obtaining the desired product (0.323 g, 0.530 mmol, 90%) as an intense yellow solid.

[0064] ^{1}H NMR ($CDCl_3$, 400 MHz) δ 8.28 (s, 1H, Ar, H-7), 8.16 (d, 1 H, J = 8.8 Hz, Ar, H-12), 7.97 (s, 1H, H-14), 7.40 (dd, 1H, J_1 = 9.2 Hz J_2 = 2.8 Hz, H-11), 7.26 (d, 1H, J = 2.8 Hz, H-9), 6.15 (d, 1 H, J = 16.8 Hz, H-17), 5.58 (d, 1 H, J = 20.0 Hz, H-5), 5.53 (d, 1H, J = 20.0 Hz, H-5), 5.33 (d, 1 H, J = 16.8 Hz, H-17), 1.91 (q, 2H, J = 7.4 Hz, H-19), 1.04 (s, 9 H), 1.02-0.92 (m, 12 H), 0.82-0.72 (m, 6 H), 0.30 (s, 6 H). ^{13}C NMR ($CDCl_3$, 100 MHz) δ 172.1, 171.5, 155.5, 149.8, 148.6, 147.3, 145.3, 131.5, 130.1, 129.8, 129.1, 128.3, 127.0. 114.5, 104.0. 75.0. 68.8, 56.3, 33.5, 25.6, 18.3, 7.8, 7.2, 6.4, -4.3.

EXAMPLE XVII - Preparation of 10-hydroxy-Thio-Camptothecin (IDN 6181)

[0065] Thio-camptothecin 10-OTBDMS 20-OTES (0.320 g, 0.524 mmols) is dissolved in anhydrous THF (8 mL) with stirring under inert atmosphere, subsequently Et3N•3HF (0.670 mL, 4.19 mmols) is dropped therein. The reaction mixture is reacted for 20 h at room temperature, monitoring by TLC the disappearance of the reagent (CH_2Cl_2/MeOH = 25/1). The solvent is evaporated off under vacuum and the residue is purified by flash chromatography (SiO_2, CH_2Cl_2/MeOH = 25/1 then 20/1), thereby obtaining the desired product (0.189 g, 0.498 mmol, 95%) as an intense yellow solid.

[0066] ^{1}H NMR (THF-d_8, 400 MHz) δ 9.20 (br s, 1 H, OH), 8.37 (s, 1 H, Ar, H-7), 8.05 (d, 1 H, J = 9.2 Hz, Ar, H-12), 7.89 (s, 1 H, H-14), 7.39 (dd, 1 H, J_1 = 9.2 Hz J_2 = 2.8 Hz, H-11), 7.22 (d, 1 H, J = 2.8 Hz, H-9), 6.07 (d, 1H, J = 17.2 Hz, H-17), 5.70 (br s, 1 H, OH), 5.47 (s, 2H, H-5), 5.33 (d, 1H, J = 16.8 Hz, H-17), 1.89 (q, 2H, J = 7.6 Hz, H-19), 0.97 (t, 3 H, J = 7.6 Hz, Me). ^{13}C NMR (THF-d_8, 100 MHz) δ 173.0. 172.1, 157.4, 149.7, 149.0. 146.1, 144.5, 131.3, 130.5,

130.2, 129.7, 128.6, 123.0. 108.9, 102.3, 72.3, 68.5, 56.5, 31.7, 7.3.

EXAMPLE XVIII - Thio-topotecan hydrochloride (IDN 6180)

[0067] 10-Hydroxy-Thio-Camptothecin (0.150 g, 0.421 mmols) is dissolved in a mixture of anhydrous CH_2Cl_2 (3.5 mL) and n-propanol (1.8 mL) with stirring under inert atmosphere. Subsequently, bis(dimethylamino)methane (0.092 g, 0.905 mmols) is dropped therein. The reaction mixture is reacted for 4 h at room temperature, monitoring by TLC the disappearance of the reagent (CH_2Cl_2/MeOH = 25/1). After about 5 h, a mixture of 0.125 g of concentrated HCl in 1 ml of n-propanol is added and the mixture is reacted for other 16 h. The product is filtered and repeatedly washed with CH_2Cl_2 and Et_2O, thereby obtaining the desired product (0.168 g, 0.370 mmol, 88%) as a red-orange solid.

[0068] ^{1}H NMR (DMSO-d_6, 400 MHz) δ 11.51 (br s, 1H, OH), 9.78 (br s, 1H, OH), 9.06 (s, 1 H, Ar, H-7), 8.21 (d, 1 H, J = 8.8 Hz, Ar), 7.76 (s, 1 H, H-14), 7.72 (d, 1 H, J = 8.8 Hz, Ar), 5.91 (d, 1H, J = 16.4 Hz, H-17), 5.50 (d, 1H, J = 16.4 Hz, H-17), 5.49 (s, 2H, H-5), 4.73 (s, 1 H, CH_2NMe_2), 4.72 (s, 1 H, CH_2NMe_2), 2.83 (s, 3 H, Me), 2.82 (s, 3 H, Me), 1.87 (q, 2H, J = 7.6 Hz, H-19), 0.85 (t, 3 H, J = 7.6 Hz, Me). ^{13}C NMR (DMSO-d_6, 100 MHz) δ 172.7, 172.1, 158.8, 149.6, 148.8, 147.0. 144.2, 133.7, 130.6, 130.6, 129.9, 127.5, 123.2, 109.1, 103.6, 72.8, 68.6, 57.4, 51.1, 43.1, 31.2, 8.3.

EXAMPLE XIX - 5-F-20-OTES-Camptothecin

[0069] Camptothecin 20-OTES (0.100 g, 0.216 mmols) is dissolved in anhydrous THF (6 mL) with stirring under inert atmosphere, then cooled to a temperature of-78°C and a 1.0 M LiHMDS solution in THF (0.260 mL, 0.260 mmols) is dropped therein. After 20', NFSI (0.089 g, 0.281 mmols) in anhydrous THF (2 mL) is added. After 2 h at -78°C, temperature is left to raise to 25°C and the disappearance of the reagent is monitored by TLC (Hexane/AcOEt = 1/2). Formation of the two diastereomers is observed. After 3 h at room temperature, the reaction is quenched by addition of saturated NH_4Cl. The aqueous phase is extracted with CH_2Cl_2 (3 x 15 mL) and the organic phases are combined, dried over Na_2SO_4, filtered and concentrated under vacuum. The residue is purified by flash chromatography (SiO_2, Hexane/AcOEt = 3/1, then 2/1 and finally 1/1), thereby obtaining a mixture of the two isomers (0.101 g, 0.210 mmol, 97%,) (1:1 isomers ratio) as a pale yellow solid. The two isomers are separated by further chromatography. In order of elution:

1st diastereomer: ^{1}H NMR ($CDCl_3$, 400 MHz) δ 8.52 (s, 1 H, Ar, H-7), 8.25 (d, 1 H, J = 8.4 Hz, Ar), 7.96 (d, 1 H, J = 8.4 Hz, Ar), 7.87 (t, 1 H, J = 8.4 Hz, Ar), 7.69 (t, 1 H, J = 8.4 Hz, Ar), 7.47 (d, 1 H, $^1J_{HF}$ = 61.2 Hz, H-5), 7.45 (s, 1 H, H-14), 5.62 (d, 1 H, J = 16.8 Hz, H-17), 5.22 (d, 1 H, J = 16.8 Hz, H-17), 2.02-1.84 (m, 2H, H-19), 1.03-0.93 (m, 12 H), 0.80-0.71 (m, 6 H). ^{13}C NMR ($CDCl_3$, 100 MHz) δ 171.4, 157.5, 152.3, 151.1, 150.2 (d, J = 1.5 Hz), 150.3 (d, J = 1.5 Hz), 143.6 (d, J = 5.3 Hz), 133.7, 131.7, 130.2, 128.9, 128.4, 127.9 (d, J = 15.0 Hz), 126.3 (d, J = 15.0 Hz), 121.8, 98.9, 93.8 (d, $^1J_{CF}$ = 213.2 Hz, C-5), 75.1, 65.7, 33.1, 7.8, 7.2, 6.4.

2nd diastereomer: ^{1}H NMR ($CDCl_3$, 400 MHz) δ 8.51 (s, 1H, Ar, H-7), 8.25 (d, 1 H, J = 8.4 Hz, Ar), 7.96 (d, 1 H, J = 8.4 Hz, Ar), 7.87 (t, 1 H, J = 8.4 Hz, Ar), 7.68 (t, 1H, J = 8.4 Hz, Ar), 7.51 (d, 1H, $^1J_{HF}$ = 60.8 Hz, H-5), 7.42 (s, 1H, H-14), 5.62 (d, 1 H, J = 17.2 Hz, H-17), 5.20 (d, 1H, J = 17.2 Hz, H-17), 2.02-1.82 (m, 2H, H-19), 1.04-0.93 (m, 12 H), 0.80-0.71 (m, 6 H). ^{13}C NMR ($CDCl_3$, 100 MHz) δ 171.2, 157.8, 152.5, 151.2, 150.3, 143.7, 133.7 (d, J = 2.4 Hz), 131.7, 130.2, 128.9, 128.3, 127.9 (d, J = 2.3 Hz), 126.3 (d, J = 16.7 Hz), 121.8 (d, J = 1.5 Hz), 99.0. 93.8 (d, $^1J_{CF}$ = 214.8 Hz, C-5), 75.0, 65.8, 33.3, 7.9, 7.1, 6.4.

EXAMPLE XX- Preparation of 5-F-20-OH-camptothecin 1st diastereomer

[0070] The first diastereomer of 5-F-20-OTES-camptothecin (0.025 g, 0.052 mmols) is dissolved in anhydrous THF (5 mL) with stirring under inert atmosphere. Subsequently Et3N•3HF (0.060 mL, 0.368 mmols) is dropped therein. The reaction mixture is reacted for 28 h at room temperature, monitoring by TLC the disappearance of the reagent (Hexane/AcOEt = 1/2). The solvent is evaporated off under vacuum and the residue is chromatographed (SiO_2, Hexane/AcOEt = 1/1), thereby obtaining the desired product (0.019 g, 0.051 mmol, 98%) as a pale yellow solid.

[0071] ^{1}H NMR ($CDCl_3$, 400 MHz) δ 8.52 (s, 1 H, Ar, H-7), 8.25 (d, 1 H, J = 8.4 Hz, Ar), 7.96 (d, 1 H, J = 8.4 Hz, Ar), 7.87 (t, 1 H, J = 8.4 Hz, Ar), 7.69 (t, 1 H, J = 8.4 Hz, Ar), 7.59 (s, 1 H, H-14), 7.46 (d, 1 H, $^1J_{HF}$ = 61.2 Hz, H-5), 5.69 (d, 1 H, J = 16.8 Hz, H-17), 5.26 (d, 1 H, J = 16.8 Hz, H-17), 3.87 (br s, 1 H, OH), 2.01-1.81 (m, 2H, H-19), 1.05 (t, 3 H, J = 7.6 Hz, Me). ^{13}C NMR ($CDCl_3$, 100 MHz) δ 173.5, 157.6, 151.1, 151.0. 150.2, 144.1, 133.9, 131.9, 130.0. 129.0. 128.5, 127.8, 126.4, 121.7, 98.8, 93.8 (d, $^1J_{CF}$ = 214.0 Hz, C-5), 72.5, 66.0, 31.5, 7.8.

EXAMPLE XXI - Preparation of 5-F-20-OH-camptothecin 2nd diastereomer

[0072] The second diastereomer of 5-F-20-OTES-camptothecin (0.025 g, 0.052 mmols) is dissolved in anhydrous THF (5 mL) with stirring under inert atmosphere, subsequently Et3N•3HF (0.060 mL, 0.368 mmols) is dropped therein.

The reaction mixture is reacted for 28 h at room temperature, monitoring by TLC the disappearance of the reagent (Hexane/AcOEt = 1/2). The solvent is evaporated off under vacuum and the residue is chromatographed (SiO_2, Hexane/AcOEt = 1/1), thereby obtaining the desired product (0.018 g, 0.050 mmol, 97%) as a pale yellow solid.

[0073] ^1H NMR ($CDCl_3$, 400 MHz) δ 8.52 (s, 1 H, Ar, H-7), 8.24 (d, 1H, *J* = 8.4 Hz, Ar), 7.96 (d, 1 H, *J* = 8.4 Hz, Ar), 7.88 (t, 1 H, *J* = 8.4 Hz, Ar), 7.69 (t, 1 H, *J* = 8.4 Hz, Ar), 7.56 (s, 1H, H-14), 7.51 (d, 1H, $^1J_{HF}$ = 60.4 Hz, H-5), 5.69 (d, 1H, *J* = 16.4 Hz, H-17), 5.25 (d, 1 H, *J* = 16.4 Hz, H-17), 3.87 (br s, 1 H, OH), 1.98-1.78 (m, 2H, H-19), 1.04 (t, 3 H, *J* = 7.6 Hz, Me). ^{13}C NMR ($CDCl_3$, 100 MHz) δ 173.3, 157.7, 151.2, 151.2, 150.2, 144.2, 133.8, 131.9, 130.0, 129.0, 128.5, 127.8, 126.4, 121.6, 98.9, 93.7 (d, $^1J_{CF}$ = 214.0 Hz, C-5), 72.5, 66.1, 31.6, 7.8.

EXAMPLE XXII - Preparation of 5-N3-20-OTES-camptothecin

[0074] Camptothecin 20-OTES (0.100 g, 0.216 mmols) is dissolved in anhydrous THF (6 mL) with stirring under inert atmosphere, then cooled to a temperature of-78°C and a 1.0 M LiHMDS solution in THF (0.260 mL, 0.260 mmols) is dropped therein. After 20 min, tosyl azide (TsN_3) (0.055 g, 0.281 mmols) in anhydrous THF (2 mL) is added. After 2 h at -78°C, temperature is left to raise to 25°C and the disappearance of the reagent is monitored by TLC (Hexane/AcOEt = 2/1). Formation of the two diastereomers is observed. After 2h 30 min at room temperature, the reaction is quenched by addition of saturated NH_4Cl. The aqueous phase is extracted with CH_2Cl_2 (3 x 15 mL) and the organic phases are combined, dried over Na_2SO_4, filtered and concentrated under vacuum. The residue, consisting of the two diastereomers, is purified by flash chromatography (SiO_2, Hexane/AcOEt = 3/1, then 2/1 and finally 1/1), thereby obtaining (0.106 g, 0.210 mmol, 97%) of a mixture of the two isomers (ratio of the isomers 1:1) as a pale yellow solid. The two isomers are separated by further chromatography. In order of elution:

1st diastereomer: ^1H NMR ($CDCl_3$, 400 MHz) δ 8.45 (s, 1H, Ar, H-7), 8.25 (d, 1 H, *J* = 8.4 Hz, Ar), 7.95 (d, 1 H, *J* = 8.4 Hz, Ar), 7.86 (t, 1 H, *J* = 8.4 Hz, Ar), 7.68 (t, 1 H, *J* = 8.4 Hz, Ar), 7.49 (s, 1 H, H-14), 6.97 (s, 1 H, H-5), 5.65 (d, 1 H, *J* = 16.8 Hz, H-17), 5.26 (d, 1H, *J* = 16.8 Hz, H-17), 2.01-1.84 (m, 2H, H-19), 1.03-0.94 (m, 12 H), 0.80-0.71 (m, 6 H). ^{13}C NMR ($CDCl_3$, 100 MHz) δ 171.6, 158.3, 152.2, 150.8, 150.0. 144.0. 132.9, 131.4, 130.1, 128.6, 128.3, 128.2, 128.1, 120.8, 98.7, 75.4, 75.2, 65.7, 33.1, 7.9, 7.2, 6.4.

2nd diastereomer: ^1H NMR ($CDCl_3$, 400 MHz) δ 8.45 (s, 1 H, Ar, H-7), 8.24 (d, 1 H, *J* = 8.4 Hz, Ar), 7.95 (d, 1 H, *J* = 8.4 Hz, Ar), 7.86 (t, 1 H, *J* = 8.4 Hz, Ar), 7.68 (t, 1 H, *J* = 8.4 Hz, Ar), 7.46 (s, 1 H, H-14), 6.99 (s, 1 H, H-5), 5.66 (d, 1 H, *J* = 16.8 Hz, H-17), 5.22 (d, 1 H, *J* = 16.8 Hz, H-17), 2.02-1.84 (m, 2H, H-19), 1.03-0.94 (m, 12 H), 0.80-0.71 (m, 6 H). ^{13}C NMR ($CDCl_3$, 100 MHz) δ 171.4, 158.4, 152.3, 150.9, 150.0, 144.0, 132.9, 131.4, 130.1, 128.6, 128.3, 128.2, 128.1, 120.8, 98.7, 75.3, 75.1, 65.8, 33.3, 7.9, 7.2, 6.4.

EXAMPLE XXIII - Preparation of 5-N3-20-OH-camptothecin 1st diastereomer

[0075] The diastereomer 1 of 5-N3-20-OTES-camptothecin (0.070 g, 0.139 mmols) is dissolved in anhydrous THF (6 mL) with stirring under inert atmosphere, subsequently Et3N•3HF (0.170 mL, 1,016 mmols) is dropped therein. The reaction mixture is reacted for 26 h at room temperature, monitoring by TLC the disappearance of the reagent (Hexane/AcOEt =1/1). The solvent is evaporated off under vacuum and the residue is purified by flash chromatography (SiO_2, Hexane/AcOEt = 1/1), thereby obtaining the desired product (0.053 g, 0.136 mmol, 98%) as a pale yellow solid.

[0076] ^1H NMR ($CDCl_3$, 400 MHz) δ 8.44 (s, 1H, Ar, H-7), 8.24 (d, 1 H, *J* = 8.4 Hz, Ar), 7.93 (d, 1 H, *J* = 8.4 Hz, Ar), 7.85 (t, 1 H, *J* = 8.4 Hz, Ar), 7.67 (t, 1 H, *J* = 8.4 Hz, Ar), 7.63 (s, 1H, H-14), 6.97 (s, 1H, H-5), 5.70 (d, 1H, *J* = 16.8 Hz, H-17), 5.29 (d, 1 H, *J* = 16.8 Hz, H-17), 3.99 (br s, 1 H, OH), 2.00-1.84 (m, 2H, H-19), 1.04 (t, 3 H, *J* = 7.6 Hz, Me). ^{13}C NMR ($CDCl_3$, 100 MHz) δ 173.6, 158.3, 150.8, 150.7, 149.8, 144.4, 133.1, 131.5, 129.9, 128.6, 128.3, 128.3, 128.1, 120.6, 98.6, 75.4, 72.7, 66.0, 31.5, 7.8.

EXAMPLE XXIV - Preparation of 5-N3-camptothecin 2nd diastereomer

[0077] The diastereomer 2 of 5-N3-20-OTES-camptothecin (0.055 g, 0.109 mmols) is dissolved in anhydrous THF (6 mL) with stirring under inert atmosphere, subsequently Et3N•3HF (0.135 mL, 0.820 mmols) is dropped therein. The reaction mixture is reacted for 26 h at room temperature, monitoring the disappearance of the starting reagent by TLC (Hexane/AcOEt = 1/1). The solvent is evaporated off under vacuum and the residue is purified by flash chromatography (SiO_2, Hexane/AcOEt = 1/1), thereby obtaining the desired product (0.042 g, 0.107 mmol, 98%) as a pale yellow solid.

[0078] ^1H NMR ($CDCl_3$, 400 MHz) δ 8.45 (s, 1 H, Ar, H-7), 8.23 (d, 1 H, *J* = 8.4 Hz, Ar), 7.95 (d, 1 H, *J* = 8.4 Hz, Ar), 7.85 (t, 1 H, *J* = 8.4 Hz, Ar), 7.68 (t, 1 H, *J* = 8.4 Hz, Ar), 7.60 (s, 1H, H-14), 7.00 (s, 1H, H-5), 5.74 (d, 1H, *J* = 16.8 Hz, H-17), 5.28 (d, 1 H, *J* = 16.8 Hz, H-17), 3.86 (br s, 1 H, OH), 1.98-1.82 (m, 2H, H-19), 1.04 (t, 3 H, *J* = 7.6 Hz, Me). ^{13}C NMR ($CDCl_3$, 100 MHz) δ 173.4, 158.4, 150.9, 150.7, 149.8, 144.5, 133.0, 131.5, 129.9, 128.6, 128.4, 128.3, 128.1, 120.6, 98.6, 75.3, 72.6, 66.1, 31.6, 7.8.

EXAMPLE XXV - Preparation of 5-NH_2-camptothecin

[0079] The diastereomer 2 of 5-N3-20-OH-camptothecin (0.050 g, 0.129 mmols) is dissolved in a mixture of anhydrous THF (1.5 mL) and anhydrous MeOH (6 mL) with stirring under inert atmosphere, subsequently is added with Pd/C (14 mg ~ 10%) and two cycles in vacuo /H_2 (H_2 balloon pressure) are carried out. The reaction mixture is reacted for 3 h at room temperature monitoring by TLC (Hexane/AcOEt = 1/3) the disappearance of the reagent, then filtered through Celite and washed with CH_2Cl_2 (2 x 15 mL). The solvent is evaporated off under vacuum. ^{1}H NMR spectroscopy of the reaction crude reveals the presence of the desired product as a 1:1 mixture of two epimers at the C5 position. Flash chromatography (SiO_2, CH_2Cl_2/MeOH - 35/1 then 25/1) allows to recovery the mixture of the two diastereomers (0.046 g, 0.126 mmol, 98%).

[0080] ^{1}H NMR ($CDCl_3$, 400 MHz) δ 8.48 (s, 1H, Ar, H-7), 8.22-8.17 (m, 1H, Ar), 7.95-7.90 (m, 1 H, Ar), 7.85-7.78 (m, 1 H, Ar), 7.68-7.60 (m, 1 H, Ar), 7.58 (s, 0.5 H, H-14), 7.54 (s, 0.5 H, H-14) 6.50 (s, 0.5 H, H-5), 6.47 (s, 0.5 H, H-5), 5.74-5.64 (m, 1H, H-17), 5.28-5.22 (m, 1H, H-17), 4.00-2.40 (br s, 3 H, OH + NH_2), 1.98-1.82 (m, 2H, H-19), 1.07-1.01 (m, 3 H, Me). ^{13}C NMR ($CDCl_3$, 100 MHz) δ 173.8 (2 C), 158.5 (2 C), 151.2 (2 C), 150.4 (2 C), 149.7 (2 C), 144.5 (2 C), 132.7 (2 C), 131.0 (2 C), 129.8 (2 C), 128.5 (2 C), 128.3 (2 C), 128.0 (2 C), 127.8 (2 C), 120.2 (2 C), 113.8 (2 C), 97.7 (2 C), 72.7 (2 C), 66.3, 66.0, 31.5 (2 C), 7.8, 7.8.

EXAMPLE XXVI - 5-di-t-Butoxycarbonylhydrazino-20-OTES-camptothecin

[0081] Camptothecin 20-OTES (0.100 g, 0.216 mmols) is dissolved in anhydrous THF (6 mL) with stirring under inert atmosphere, then cooled to a temperature of-78°C and a 1.0 M LiHMDS solution in THF (0.281 mL, 0.281 mmols) is dropped therein. After 20', di-tert-butylazo dicarboxylate (DTBAC) (0.075 g, 0.324 mmols) in anhydrous THF (2 mL) is added. After 4 h at -78°C, the disappearance of the reagent is monitored by TLC (Hexane/AcOEt = 3/1). Formation of the two diastereomers is observed. The reaction is quenched by addition of saturated NH_4Cl. The aqueous phase is extracted with CH_2Cl_2 (3 x 15 mL) and the organic phases are combined, dried over Na_2SO_4, filtered and concentrated under vacuum. The residue is purified by flash chromatography (SiO_2, Hexane/AcOEt = 3/1), thereby obtaining a mixture of the two isomers (0.145 g, 0.210 mmol, 97%). The two isomers are separated by further chromatography. In order of elution:

1st diastereomer ^{1}H NMR ($CDCl_3$, 400 MHz) δ 8.80 (br s, 1 H, Ar), 8.23 (d, 1 H, *J* = 8.4 Hz, Ar), 8.01 (br d, 1 H, Ar), 7.90-7.71 (m, 2H, Ar), 7.70-7.45 (m, 2H, Ar + H-14), 6.52 (br s, 1H, H-5), 5.61 (d, 1H, *J* = 16.8 Hz, H-17), 5.23 (d, 1H, *J* = 16.8 Hz, H-17), 2.03-1.81 (m, 2H, H-19), 1.79-1.08 (br s, 18 H), 1.06-0.92 (m, 12 H), 0.80-0.70 (m, 6 H). ^{13}C NMR ($CDCl_3$, 100 MHz) δ 171.7, 157.8, 155.5, 155.5, 152.0, 152.0, 151.2, 149.4, 145.0, 132.1, 130.6, 130.0, 128.7, 128.4, 127.9, 119.9, 98.2, 82.7, 81.5, 79.7, 75.2, 65.7, 33.2, 28.3, 27.6, 7.7, 7.2, 6.4.

2nd diastereomer: ^{1}H NMR ($CDCl_3$, 400 MHz) δ 8.79 (br s,1 H, Ar), 8.23 (d, 1 H, *J* = 8.4 Hz, Ar), 8.01 (br d, 1 H, Ar), 7.85-7.76 (m, 2H, Ar), 7.65 (br t, 1 H, *J* = 8.4 Hz, Ar), 7.52 (s, 1H, H-14), 6.54 (br s, 1H, H-5), 5.61 (d, 1H, *J* = 16.8 Hz, H-17), 5.22 (d, 1H, *J* = 16.8 Hz, H-17), 2.03-1.82 (m, 2H, H-19), 1.76-1.08 (br s, 18 H), 1.04-0.92 (m, 12 H), 0.80-0.70 (m, 6 H). ^{13}C NMR ($CDCl_3$, 100 MHz) δ 171.5, 157.9, 155.5, 155.5, 152.3, 152.0. 151.2, 149.4, 145.1, 132.1, 130.6, 130.0, 128.7, 128.4, 127.9, 119.9, 98.2, 82.9, 81.5, 79.6, 75.2, 65.8, 33.3, 28.3, 27.4, 7.8, 7.2, 6.4.

EXAMPLE XXVII - Preparation of 5-di-*t*-butoxycarbonylhydrazino-20-OH-camptothecin 1st diastereomer

[0082] 5-di-*t*-Butoxycarbonylhydrazino-20-OTES-camptothecin (0.050 g, 0.072 mmols) first diastereomer is dissolved in anhydrous THF (4 mL) with stirring under inert atmosphere, subsequently Et_3N•3HF (0.088 mL, 0.542 mmols) is dropped therein. The reaction mixture is reacted for 35 h at room temperature, monitoring by TLC the disappearance of the reagent (Hexane/AcOEt = 3/2). The solvent is evaporated off under vacuum and the residue is purified by flash chromatography (SiO_2, Hexane/AcOEt = 3/2), thereby obtaining the desired compound (0.041 g, 0.071 mmol, 98%) as a pale yellow solid.

[0083] The product is further purified by crystallization from CH_2Cl_2/Pentane = 1/50.

[0084] ^{1}H NMR ($CDCl_3$, 400 MHz) δ 8.77 (br s, 1 H, Ar), 8.16 (br d, 1 H, *J* = 8.0 Hz, Ar), 7.97 (br s, 1 H, Ar), 7.86-7.50 (m, 4 H, Ar), 6.51 (br s, 1 H, H-5), 5.66 (d, 1 H, *J* = 16.4 Hz, H-17), 5.24 (d, 1 H, *J* = 16.4 Hz, H-17), 3.86 (br s, 1 H, OH), 2.00-1.80 (m, 2H, H-19), 1.79-1.13 (br s, 18 H), 1.03 (t, 3 H, *J* = 7.6 Hz, Me). ^{13}C NMR ($CDCl_3$, 100 MHz) δ 173.7, 157.9, 155.5, 155.5, 152.1, 151.3, 150.7, 149.6, 145.7, 132.3, 130.7, 129.9, 128.7, 127.9, 127.6, 120.0, 97.9, 82.8, 81.6, 79.7, 72.7, 66.1, 31.8, 28.3, 27.7, 7.7.

EXAMPLE XXVIII- Preparation of 5-di-*t*-butoxycarbonylhydrazino-20-OH-camptothecin 2nd diastereomer

[0085] 5-di-*t*-Butoxycarbonylhydrazino-20-OTES-camptothecin (0.050 g, 0.072 mmols) 2nd diastereomer is dissolved

in anhydrous THF (4,5 mL) with stirring under inert atmosphere, subsequently Et_3N•3HF (0.088 mL, 0.542 mmols) is dropped therein. The reaction mixture is reacted for 35 h at room temperature, monitoring by TLC the disappearance of the reagent (Hexane/AcOEt = 3/2). The solvent is evaporated off under vacuum and the residue is purified by flash chromatography (SiO_2, Hexane/AcOEt = 3/2), thereby obtaining the desired compound (0.040 g, 0.069 mmol, 96%) as a pale yellow solid.

[0086] The product is further purified by crystallization from CH_2Cl_2/Pentane = 1/50.

[0087] ^{1}H NMR ($CDCl_3$, 400 MHz) δ 8.79 (br s, 1 H, Ar), 8.22 (br d, 1 H, *J* = 8.4 Hz, Ar), 7.99 (br s, 1 H, Ar), 7.88-7.50 (m, 4 H, Ar), 6.53 (br s, 1 H, H-5), 5.65 (d, 1 H, *J* = 16.4 Hz, H-17), 5.26 (d, 1 H, *J* = 16.4 Hz, H-17), 3.80 (br s, 1 H, OH), 2.00-1.80 (m, 2H, H-19), 1.79-1.13 (br s, 18 H), 1.03 (t, 3 H, *J* = 7.2 Hz, Me). ^{13}C NMR ($CDCl_3$, 100 MHz) δ 173.6, 157.9, 155.4, 155.4, 152.1, 151.3, 150.8, 149.5, 145.6, 132.3, 130.8, 129.8, 128.7, 127.9, 127.8, 119.8, 98.0, 83.0, 81.5, 79.7, 72.7, 66.3, 31.8, 28.3, 27.7, 7.8.

EXAMPLE XXIX - Preparation of 5-dibenzyloxycarbonylhydrazino-20-OTES-camptothecin

[0088] Camptothecin 20-OTES (0.100 g, 0.216 mmols) is dissolved in anhydrous THF (6 mL) with stirring under inert atmosphere, then cooled to a temperature of-78°C and a 1.0 M LiHMDS solution in THF (0.281 mL, 0.281 mmols) is dropped therein. After 20', dibenzyl azodicarboxylate (0.097 g, 0.324 mmols) in anhydrous THF (2 mL) is added. After 3 h at -78°C, temperature is left to raise to 25°C and the disappearance of the reagent is monitored by TLC (Hexane/AcOEt = 3/1). Formation of the two diastereomers is observed. After 90 min at room temperature, the reaction is quenched by addition of saturated NH_4Cl. The aqueous phase is extracted with CH_2Cl_2 (3 x 15 mL) and the organic phases are combined, dried over Na_2SO_4, filtered and concentrated under vacuum. The residue is purified by flash chromatography (SiO_2, Hexane/AcOEt = 4/1 then 7/2), thereby obtaining a pale yellow solid (0.161 g, 0.212 mmol, 98%). The two isomers are separated by further chromatography. In order of elution:

1st diastereomer: ^{1}H NMR ($CDCl_3$, 400 MHz) δ 8.70 (br s, 1H, Ar), 8.39 (br s 1 H, Ar), 8.22 (br d, 1H, *J* = 7.6 Hz, Ar), 7.95 (br d, 1 H, *J* = 7.6 Hz, Ar), 7.83 (br t, 1 H, *J* = 7.6 Hz, Ar), 7.65 (br t, 1 H, *J* = 7.6 Hz, Ar), 7.64-7.00 (m, 11 H, Ar + H-14), 6.49 (br s, 1H, H-5), 5.57 (d, 1 H, *J* = 16.4 Hz, H-17), 5.47-4.44 (m, 5 H), 1.98-1.82 (m, 2H, H-19), 1.02-0.89 (m, 12 H), 0.80-0.70 (m, 6 H). ^{13}C NMR ($CDCl_3$, 100 MHz) δ 171.6, 158.0. 156.3, 156.3, 153.0, 152.2, 151.0, 149.6, 144.8, 135.3, 132.1, 130.6, 130.0, 128.6-127.8 (11 C), 119.9, 98.4, 79.5, 75.2, 68.4, 67.9, 65.6, 33.0. 7.9, 7.2, 6.4.

2nd diastereomer: ^{1}H NMR ($CDCl_3$, 400 MHz) δ 8.85 (br s, 1 H, Ar), 8.58 (br s 1 H, Ar), 8.20 (br s, 1H, Ar), 7.93 (br s, Ar), 7.81 (br t, 1 H, *J* = 7.6 Hz, Ar), 7.63 (br t, 1 H, *J* = 7.6 Hz, Ar), 7.56-6.90 (m, 11 H, Ar + H-14), 6.52 (br s, 1 H, H-5), 5.55 (d, 1H, *J* = 16.8 Hz, H-17), 5.44-4.71 (m, 5 H), 1.98-1.80 (m, 2H, H-19), 1.05-0.90 (m, 12 H), 0.81-0.70 (m, 6 H). ^{13}C NMR ($CDCl_3$, 100 MHz) δ 171.5, 157.9, 156.4, 156.4, 152.9, 152.4, 150.9, 149.4, 144.8, 135.3, 132.1, 130.6, 129.9, 128.6-127.8 (11 C), 119.9, 98.5, 79.3, 75.2, 68.4, 67.8, 65.6, 32.9, 7.8, 7.2, 6.4.

EXAMPLE XXX - Preparation of 5-dibenzyloxycarbonylhydrazino-20-OH-camptothecin 1st diastereomer

[0089] 5-Dibenzyloxycarbonylhydrazino-20-OTES-camptothecin 1st diastereomer (0.140 g, 0.184 mmols) is dissolved in anhydrous THF (6 mL) with stirring under inert atmosphere, subsequently Et_3N•3HF (0.225 mL, 1,380 mmols) is dropped therein. The reaction mixture is reacted for 52 h at room temperature, monitoring by TLC the disappearance of the reagent (Hexane/AcOEt = 1/3). The solvent is evaporated off under vacuum and the residue is purified by flash chromatography (SiO_2, Hexane/AcOEt = 1/1 then 2/3), thereby obtaining (0.113 g, 0.175 mmol, 95%) as a pale yellow solid. The product is further purified by crystallization from CH_2Cl_2/Pentane = 1/50.

[0090] ^{1}H NMR ($CDCl_3$, 400 MHz) δ 8.67 (br s, 1 H, Ar), 8.39 (br s 1 H, Ar), 8.12 (br d, 1 H, *J* = 7.6 Hz, Ar), 7.95 (br s, 1 H, Ar), 7.74 (br t, 1 H, *J* = 7.6 Hz, Ar), 7.65-6.66 (m, 12H, Ar + H-14), 6.48 (br s, 1H, H-5), 5.55 (d, 1H, *J* = 16.0 Hz, H-17), 5.42-4.44 (m, 5 H), 3.86 (br s, 1 H, OH), 1.92-1.72 (m, 2H, H-19), 0.95 (t, 3 H, *J* = 7.6 Hz, Me). ^{13}C NMR ($CDCl_3$, 100 MHz) δ 173.5, 158.0, 156.2, 156.0, 153.0, 150.9, 150.9, 149.5, 145.3, 135.4, 132.2, 130.7, 129.8, 128.7-127.8 (11 C), 119.9, 98.2, 79.6, 72.7, 68.5, 68.0, 165.9, 31.6, 7.8.

EXAMPLE XXXI - Preparation of 5-dibenzyloxycarbonylhydrazino-20-OH-camptothecin 2nd diastereomer

[0091] 5-Dibenzyloxycarbonylhydrazino-20-OTES-camptothecin 2nd diastereomer (0.140 g, 0.184 mmols) is dissolved in anhydrous THF (6 mL) with stirring under inert atmosphere, subsequently Et_3N•3HF (0.150 mL, 0.921 mmols) is dropped therein. The reaction mixture is reacted for 55 h at room temperature, monitoring by TLC the disappearance of the reagent (Hexane/AcOEt = 3/2). The solvent is evaporated off under vacuum and the residue is purified by flash chromatography (SiO_2, Hexane/AcOEt = 1/1), thereby obtaining the desired compound (0.113 g, 0.175 mmol, 95%) as a pale yellow solid. The product is further purified by crystallization from CH_2Cl_2/Pentane = 1/50.

[0092] ^{1}H NMR ($CDCl_3$, 400 MHz) δ 8.71 (br s, 1H, Ar), 8.34 (br s 1H, Ar), 8.18 (br s, 1 H, Ar), 7.94 (br s, 1H, Ar), 7.79 (br t, 1 H, *J* = 7.6 Hz, Ar), 7.70-6.70 (m, 12H, Ar + H-14), 6.52 (br s, 1H, H-5), 5.53 (d, 1H, *J* = 16.4 Hz, H-17), 5.44-4.48 (m, 5 H), 3.87 (br s, 1H, OH), 1.90-1.70 (m, 2H, H-19), 0.99 (t, 3 H, *J* = 7.6 Hz, Me). ^{13}C NMR ($CDCl_3$, 100 MHz) δ 173.4, 158.0, 156.3, 156.1, 153.0. 151.0. 150.9, 149.6, 145.3, 135.5, 132.3, 130.8, 129.8, 128.7, 127.8 (11 C), 119.8, 98.4, 79.5, 72.7, 68.5, 67.8, 66.0. 31.6, 7.7.

EXAMPLE XXXII - Preparation of 20-OTES-Gimatecan

[0093] Gimatecan (0.040 g, 0.089 mmol) is dissolved in anhydrous dimethyl formamide (4 mL), under inert atmosphere, and added with imidazole (0.030 g, 0.445 mmol). The mixture is stirred for 10' minutes, subsequently triethyl silyl chloride (TES-Cl) (0.060 mL, 0.358 mmol) is dropped therein, followed by 4-dimethylaminopyridine (DMAP) (0.01 1 g 0.089 mmol). After 75 h, the reaction mixture is evaporated under vacuum, monitoring by TLC (Hexane/AcOEt = 1/1) the complete disappearance of the reagent. The solid is subsequently redissolved in CH_2Cl_2 and H_2O e saturated NH_4Cl, the aqueous phase is extracted with CH_2Cl_2 (3 X 10 mL). The residue is purified by flash chromatography (SiO_2, Hexane/AcOEt = 1/1), thereby obtaining the desired product (0.048 g, 0.085 mmols, 95%) as a yellow solid. (mixture E/Z = 70130).

[0094] ^{1}H NMR ($CDCl_3$, 400 MHz) δ 9.02 (s, 1 H, C*H*=N *E*) 8.29 (d, 1 H, *J* = 8.42 Hz, Ar, H-12*E* + H-12Z), 8.23 (d, 1H, *J* = 7.6 Hz, H-9*E*), 8.00 (s, 1H, C*H*=N *Z*), 7.99 (d, 1 H, *J* = 7.6 Hz, H-9*Z*), 7.83 (t, 1 H, *J* = 7.4 Hz, H-11*E* + H-11Z), 7.68 (t, 1 H, *J* = 7.4 Hz, H-1O*E* + H-10Z), 7.57 (s, 1H, H-14*E* + H-14*Z*, 5.67 (d, 1H, *J* = 16.4 Hz, H-17*E* + H-17Z), 5.43 (s, 2H, H-5*E*), 5.26 (d, 1 H, *J* = 16.4 Hz, H-17*E*), 5.25 (d, 1 H, *J* = 16.4 Hz, H-17Z), 5.20 (s, 2H, H-5*Z*), 2.00-1.84 (m, 2H, H-19*E*+ H-19*Z*), 1.50 (s, 9 H, o^{t}Bu*E*), 1.35 (s, 9 H, O^{t}BUZ), 1.02-0.94 (m, 12H, *E* + *Z*), 0.80-0.70 (m, 6H, E + Z). ^{13}NMR ($CDCl_3$, 100 MHz) δ 171.9 (*E* + *Z*, C-21), 157.5 (*E* + *Z*, C-16a), 152.5 (*E*), 152.3 (*Z*), 151.3 (*E* + *Z*), 149.7 (*E*), 149.0 (*Z*), 145.7 (*E* + *Z*), 142.2 (*C*H=N E), 139.4 (*C*H=N *Z*), 132.9 (*E*), 132.1 (*Z*), 130.9 (*E*, *C*H, Ar), 130.6 (*Z*, *C*H, Ar), 130.3 (*Z*, *C*H; Ar), 130.1 (*E*, *C*H, Ar), 128.1 (*E* + *Z*, CH, Ar), 125.6 (*Z*), 125.4 (*E*), 124.7 (*Z*, C*H*, Ar), 122.8 (*E*, *C*H, Ar), 119.1 (*Z*), 118.9 (*E*), 98.3 (*Z*, C-14), 98.1 (*E*, *C*-l4), 81.4 (*E*, O*C*(CH_3)$_3$), 81.2 (*Z*, O*C*(CH_3)$_3$), 75.3 (*E* + *Z*, *C*-20), 66.0 (*E* + *Z*, *C*-17), 52.7 (*E*, *C*-5), 51.2 (*Z*, *C*-5), 33.3 (*E*, *C*-19), 33.2 (*Z*, *C*- 19), 27.6 (OC(CH_3)$_3$ *E*), 27.5 (OC(CH_3)$_3$ *Z*), 7.9 (E+Z *C*-18), 7.2 (*E*+*Z*), 6.4 (*E*+*Z*).

EXAMPLE XXXIII - Preparation of of 20-OTES-Thio-Gimatecan

[0095] Gimatecan 20-OTES (0.080 g, 0.143 mmol) is dissolved in anhydrous xylene (6 mL) under stirring and inert atmosphere. Subsequently, Lawesson's reagent (LR), (0.087 g, 0.214 mmol) is added, and the reaction is heated to 90°C. The reaction mixture is reacted for 18 h 90°C, monitoring by TLC (Hexane/AcOEt = 3/1) the disappearance of the reagent. The solvent is evaporated under vacuum and the residue is purified by flash chromatography (SiO_2, Hexane/AcOEt = 4/1), thereby obtaining the desired product (0.060 g, 0.102 mmols, 71%) as an intense yellow solid.

[0096] ^{1}H NMR ($CDCl_3$, 400 MHz) δ 9.06 (s, I H, C*H*=N*E*) 8.33 (d, 1H, *J* = 8.4 Hz, Ar, H-12*E*), 8.27 (d, 1 H, *J* = 7.6 Hz, H-9*E*), 8.02 (s, I H, H-14 *E*), 7.87 (t, 1 H, *J* = 7.4 Hz, H-11*E*), 7.73 (t, 1H, *J* = 7.4 Hz, H-10*E*), 7.57 (s, 1H, H-14*E* + H-14*Z*), 6.18 (d, 1H, *J* = 17.2 Hz, H-17*E*), 5.73 (s, 2H, H-5*E*), 5.35 (d. 1 H, *J* = 17.2 Hz, H-17*E*), 1.93 (q, 2H, *J* = 7.2 Hz, H-19*E*), 1.55 (s, 9 H, O^{t}BU*E*), 1.06-0.92 (m, 12H, *E*), 0.82-0.72 (m, 6H, *E*). ^{13}C NMR ($CDCl_3$, 100 MHz) δ 172.4, 171.5, 151.8, 149.8, 148.0, 146.9, 141.9, 132.3, 131.0, 130.7, 130.3, 128.4, 125.6, 125.1, 122.9, 104.3, 81.8, 75.0, 68.9, 59.2, 33.6, 27.6, 7.8, 7.2, 6.5.

EXAMPLE XXXIV - Preparation of Thio-Gimatecon

[0097] Thio-Gimatecan 20-OTES (0.060 g, 0.104 mmol) is dissolved in anhydrous THF (8 mL) with stirring under inert atmosphere, subsequently Et_3N•3HF (0.127 mL, 0.780 mmol) is dropped therein. The reaction mixture is reacted for 18 h at room temperature, monitoring by TLC (CH_2CL_2/MeOH = 25/1) the disappearance of the reagent. The solvent is evaporated under vacuum and the residue is purified by flash chromatography (SiO_2, Hexane/AcOEt = 211), thereby obtaining the desired product (0.048 g, 0.102 mmols, 95%) as an intense yellow solid.

[0098] ^{1}H NMR ($CDCl_3$, 400 MHz) δ 9.02 (s, 1H, C*H*=N *E*) 8.28 (d, 1H, *J* = 8.42 Hz, Ar, H-12*E* + H-12Z), 8.23 (d, 1H, *J* = 7.6 Hz, H-9*E*), 8.09 (brs, 1H, H-14*E* + H-14*Z*), 8.08 (s,1 H, C*H*=NZ), 8.04 (d, 1 H, *J* = 7.6 Hz, H-9*Z*), 7.85 (t, 1 H, *J* = 7.4 Hz, H-11*E* + H-11*Z*), 7.70 (t, 1H, *J* = 7.4 Hz, H-1O*E* + H-1O*Z*), 6.26 (d, 1 H, *J* = 16.8 Hz, H-17*E*), 6.24 (d, 1H, *J* = 16.8 Hz, H-17*Z*), 5.67 (s, 2H, H-5*E*), 5.51 (s, 2H, H-5*Z*), 5.37 (d, 1 H, *J* = 16.4 Hz, H-17*E* + H-17*Z*), 3.87 (br s, 1 H, OH), 1.89 (q, 2H, H-19E + H-19Z), 1.55 (s, 9H, 0^{t}Bu*Z*), 1.42 (s, 9H, O^{t}Bu *Z*), 1.03 (t, 3 H, *J* = 7.2 Hz, H-18 Z), 1.02 (t, 3 H, *J* = 7.2 Hz, H-18 *E*). ^{13}C NMR ($CDCl_3$, 100 MHz) δ 173.5, 172.5, 151.7, 149.7, 148.4, 145.2, 141.9 (*C*H=N *E*), 139.0 (*C*H=N *Z*), 132.3, 130.8, 130.6, 130.5, 128.5, 125.5, 125.0, 122.9, 104.0, 81.8, 72.3, 69.3, 59.2, 32.1, 27.6, 7.7.

EXAMPLE XXXV - Cell growth inhibition assay

[0099] H460 Cells from human large cell lung tumor were cultured in RPMI-1640 medium containing 10% foetal calf serum. Cell sensitivity was determined by cell growth inhibition assay after 1 or 72 hr drug exposure. The cells in logarithmic growth were collected and seeded in duplicate in 6-wells plates. Twenty-four hours after seeding, cells were exposed to the drugs and counted with a Coulter conter 72 hours after exposure to the drugs for the determination of IC_{50}s. IC_{50} is defined as the concentration inhibiting by 50% cell growth compared with untreated controls growth.

EXAMPLE XXXVI - Topoisomerase-I - dependent DNA rupture assay

[0100] DNA ruptures were determined using a 751-bp BamHI-EcoRI DNA SV40 purified gel (Beretta GL, Binaschi M, Zagni AND, Capuani L, Capranico G. Tethering a type IB topoisomerase to a DNA site by enzyme fusion to a heterologous site-selective DNA-binding protein domain. Cancer Res 1999; 59:3689-97). DNA fragments were only labeled at 3'. The DNA rupture reaction (20,000 cpm/sample) was carried out in 20 ml of 10 mM Tris-HCL (pH 7.6), 150 mM KCl, 5 mM $MgCl_2$, 15 μg/mL BSA, 0.1 mM thiothreitol, and the human recombinant enzyme (full length top1) for 30 min at 37°C. The reactions were blocked using 0.5% SDS and 0.3 mg/mL K proteinase for 45 min. at 42°C. DNA damage persistence was tested at different times adding 0.6 M NaCl after 30 min. incubation with 10 μM of the drug. After precipitation, DNA was resuspended in denaturation buffer (80% formamide, 10 mM NaOH, 0.01 M EDTA and 1 mg/mL dye) before seeding in denaturating gel (7% polyacrylamide in TBE buffer). All of DNA rupture levels were measured by means of a Phospholmager model 425 (Molecular Dynamics) (Dallavalle S, Ferrari A, Biasotti B, et al. Novel 7-oxyiminomethyl camptothecin derivatives with potent in vitro and in vivo antitumor activity. J Med Chem 2001; 44:3264-74).

Persistence of DNA damage (%)

Compounds	Time (min)			
	0	1	5	10
Topotecan	100	65	20	10
Camptothecin	100	58	23	20
SN38	100	60	33	28
IDN 6070	100	33	10	10
IDN 6181	100	88	50	22
IDN 6156	100	100	80	60
IDN 6092	100	35	18	15

Claims

1. Compounds of general formula I:



(I)

wherein:

R is F, Cl, Br, I, -N3, NH2, -NR'R", -COOR', -CONR'R",-NHR"'-NR'R" in which R', R" and R'" can be H, alkyl, aryl, arylalkyl, acyl, alkoxycarbonyl, aryloxycarbonyl;
R1 is alkyl, aminoalkyl, hydroxyalkyl, nitrile, -NH-O-alkyl, , -NH-O-aryl , silylalkyl;
R2 is hydrogen, hydroxyl, alkoxy, aminoalkyl;
R3 is hydrogen, alkoxy, aminoalkyl,
wherein the alkyl groups, acyl, alkoxy, aminoalkyl or -NH-O-alkyl can contain 1 to 8 carbon atoms, in a straight or branched chain, and the groups aryl and
aryloxy can contain 5 to 10 carbon atoms;

the pharmaceutically acceptable salts, enantiomers, diastereomers thereof and corresponding mixtures.

2. A compound according to claim 1 wherein the alkyl groups, acyl, alkoxy, aminoalkyl or -NH-O-alkyl contain 1 to 4 carbon atoms.

3. A compound selected from the group consisting of:

a) thio-camptothecin;
b) thio-homocamptothecin;
c) thioSN38;
d) thio-topotecan;
e) thioirinotecan;
f) thiogimatecan.

4. A process for the preparation of compounds of formula (I), comprising the steps shown in Scheme I, wherein:

a) protection of hydroxy precursor groups;
b) conversion of the pyridone ring to thiopyridone ring;
c) removal of the protective groups;

Scheme I



wherein R, R1, R2 and R3 have the meanings described above and PG is an OH-protecting group.

5. A process for the preparation of the compounds of formula (I), comprising the steps shown in Scheme II, wherein:

a) protection of the precursor hydroxy groups;
b) derivatization at 5 through formation of a carbanion and reaction with an electrophilic reagent;
c) transformation of the 16a carbonyl into thiocarbonyl;
d) deprotection of the hydroxy groups;
in which steps b) and c) can be reversed:



Scheme II

wherein R, R1, R2 and R3 have the meanings described above and PG is an OH-protecting group.

6. A pharmaceutical composition containing a compound of formula (I) together with pharmaceutically acceptable carriers and excipients.

7. A pharmaceutical composition as claimed in claim 6, which is in a form suited to the oral or parenteral administration.

8. The use of a compound as claimed in claims 1-3 or of a composition as claimed in claims 6-7 for the preparation of a drug for the treatment of tumors.

9. The use as claimed in claim 8, wherein said drug is used for the treatment of solid tumors and leukemias.

10. The use as claimed in claim 9 wherein the solid tumors and leukemias are selected from tumors of the lung, ovary,

breast, stomach, liver, prostate, soft tissues sarcomas, esophagus, pancreas, head and neck, glioblastoma, chronic and acute myelocytic leukemias.

Patentansprüche

1. Verbindungen der allgemeinen Formel I:



(I)

worin:

R F, Cl, Br, I, -N_3, NH_2, -NR'R", -COOR', -CONR'R", -NHR"'-NR'R" darstellt, in welchen R', R" und R"' H, Alkyl, Aryl, Arylalkyl, Acyl, Alkoxycarbonyl, Arylo-xycarbonyl sein können;
R1 Alkyl, Aminoalkyl, Hydroxyalkyl, Nitril, -NH-O-Alkyl, -NH-O-Aryl, Silylalkyl darstellt;
R2 Wasserstoff, Hydroxyl, Alkoxy, Aminoalkyl darstellt;
R3 Wasserstoff, Alkoxy, Aminoalkyl darstellt, worin die Alkyl-Gruppen, Acyl, Alkoxy, Aminoalkyl oder -NH-O-Alkyl 1 bis 8 Kohlenstoff-Atome in einer geraden oder verzweigten Kette enthalten können, und die Gruppen Aryl und Aryloxy 5 bis 10 Kohlenstoff-Atome enthalten können;

die pharmazeutisch verträglichen Salze, Enantiomere, Diastereomere davon und entsprechende Gemische.

2. Verbindung nach Anspruch 1, wobei die Alkylgruppen, Acyl, Alkoxy, Aminoalkyl oder -NH-O-Alkyl 1 bis 4 Kohlenstoff-Atome enthalten.

3. Verbindung, ausgewählt aus der Gruppe, bestehend aus:

a) Thio-camptothecin;
b) Thio-homocamptothecin;
c) ThioSN38;
d) Thio-topotecan;
e) Thioirinotecan;
f) Thiogimatecan.

4. Verfahren zur Herstellung von Verbindungen der Formel (I), umfassend die in Schema I gezeigten Schritte, wobei:

a) Schutz von Hydroxy-Vorstufen-Gruppen;
b) Umwandlung des Pyridon-Rings zum Thiopyridon-Ring;
c) Entfernung der Schutz-Gruppen;

Schema I



worin R, R1, R2 und R3 die vorstehend beschriebenen Bedeutungen aufweisen und PG eine OH-Schutz-Gruppe ist.

5. Verfahren zur Herstellung der Verbindungen der Formel (I), umfassend die in Schema II gezeigten Schritte, wobei:

a) Schutz der Vorstufen-Hydroxy-Gruppen;
b) Derivatisierung an 5 durch Bildung von einem Carbanion und Umsetzung mit einem elektrophilen Reagenz;
c) Überführung des 16a-Carbonyls in Thiocarbonyl;
d) Schutz-Gruppen-Entfernung der Hydroxy-Gruppen;
in welchem Schritte b) und c) umgekehrt werden können:



Schema II

worin R, R1, R2 und R3 die vorstehend beschriebenen Bedeutungen aufweisen und PG eine OH-Schutz-Gruppe ist.

6. Pharmazeutische Zusammensetzung, enthaltend eine Verbindung der Formel (I) zusammen mit pharmazeutisch verträglichen Trägern und Exzipienten.

7. Pharmazeutische Zusammensetzung nach Anspruch 6, die in einer zur oralen oder parenteralen Verabreichung geeigneten Form vorliegt.

8. Verwendung einer Verbindung nach Ansprüchen 1-3 oder von einer Zusammensetzung nach Ansprüchen 6-7 zur Herstellung eines Arzneistoffs für die Behandlung von Tumoren.

9. Verwendung nach Anspruch 8, wobei der Arzneistoff für die Behandlung von festen bzw. soliden Tumoren und Leukämien verwendet wird.

10. Verwendung nach Anspruch 9, wobei die festen bzw. soliden Tumoren und Leukämien ausgewählt sind aus Tumoren von Lunge, Ovarien, Brust, Magen, Leber, Prostata, Weichgewebs-Sarkomen, Ösophagus, Pankreas, Kopf und Hals, Glioblastom, chronischen und akuten myelozytischen Leukämien.

Revendications

1. Composés de formule générale I :



(I)

où :

R est F, Cl, Br, I, -N_3, NH_2, -NR'R", -COOR', -CON R'R",-NHR"'-NR'R" où R',
R" et R"' peuvent être un atome H, un groupe alkyle, aryle, arylalkyle, acyle, alcoxycarbonyle, aryloxycarbonyle ;
R1 est un groupe alkyle, aminoalkyle, hydroxyalkyle, nitrile, -NH-O-alkyle, -NH-O-aryle, silylalkyle ;
R2 est un atome d'hydrogène, un groupe hydroxyle, alkoxy, aminoalkyle ;
R3 est un atome d'hydrogène, un groupe alkoxy, aminoalkyle, où les groupes alkyle, acyle, alkoxy, aminoalkyle ou -NH-O-alkyle peuvent contenir 1 à 8 atomes de carbone, dans une chaîne linéaire ou ramifiée, et les groupes aryle et aryloxy peuvent contenir 5 à 10 atomes de carbone ;
leurs sels, énantiomères, diastéréomères pharmaceutiquement acceptables et les mélanges correspondants.

2. Composé selon la revendication 1 où les groupes alkyle, acyle, alkoxy, aminoalkyle ou -NH-O-alkyle contiennent 1 à 4 atomes de carbone.

3. Composé sélectionné dans le groupe constitué de :

a) la thio-camptothécine ;
b) la thio-homocamptothécine ;
c) le thioSN38 ;
d) le thio-topotécan ;
e) le thioirinotécan ;
f) le thiogimatécan.

4. Procédé de préparation des composés de formule (1) comprenant les étapes présentées dans le schéma I, où :

a) protection des groupes précurseurs hydroxy ;
b) conversion du cycle pyridone en cycle thiopyridone ;
c) élimination des groupes protecteurs ;

Schéma I



où R, R1, R2 et R3 ont les significations décrites ci-dessus et PG est un groupe OH- protecteur.

5. Procédé de préparation des composés de formule (I), comprenant les étapes présentées dans le schéma II, où :

a) protection des groupes précurseurs hydroxy ;
b) dérivatisation à 5 jusqu'à la formation d'un carbanion et réaction avec un réactif électrophile ;
c) transformation du carbonyle 16a en thiocarbonyle ;
d) déprotection des groupes hydroxy dans lequel les étapes b) et c) peuvent être inversées :



Schéma II

où R, R1, R2 et R3 ont les significations décrites ci-dessus et PG est un groupe OH- protecteur.

6. Composition pharmaceutique contenant un composé de formule (I) conjointement à des supports et excipients pharmaceutiquement acceptables.

7. Composition pharmaceutique telle que revendiquée selon la revendication 6, qui se présente sous une forme convenant à l'administration par voie orale ou parentérale.

8. Utilisation d'un composé tel que revendiqué selon les revendications 1 à 3 ou d'une composition telle que revendiquée selon les revendications 6 à 7 pour la préparation d'un médicament pour le traitement de tumeurs.

9. Utilisation telle que revendiquée selon la revendication 8, où ledit médicament est utilisé pour le traitement des tumeurs solides et des leucémies.

10. Utilisation telle que revendiquée selon la revendication 9 où les tumeurs solides et les leucémies sont sélectionnées parmi les tumeurs du poumon, de l'ovaire, du sein, de l'estomac, du foie, de la prostate les sarcomes des tissus mous, les tumeurs de l'oesophage, du pancréas, de la tête et du cou, les glioblastomes, les leucémies myélocytaires chroniques et aiguës.

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 5972955 A **[0014]**

Non-patent literature cited in the description

- **WALL ; WANI.** *J. Am. Chem. Soc.,* 1966, vol. 88, 3888-3890 **[0002]**
- **CAVA P.M. et al.** *Tetrahedron,* 1985, vol. 41, 5061 **[0023]**
- **CHERKASOV RA et al.** *Tetrahedron,* 1985, vol. 41, 2567 **[0023]**
- **GHATTAS AAG et al.** *Sulfur Lett.,* 1982, vol. 1, 69 **[0023]**
- **YDE B et al.** *Tetrahedron,* 1984, vol. 40, 2047 **[0023]**
- **BERETTA GL ; BINASCHI M ; ZAGNI AND ; CAPUANI L ; CAPRANICO G.** Tethering a type IB topoisomerase to a DNA site by enzyme fusion to a heterologous site-selective DNA-binding protein domain. *Cancer Res,* 1999, vol. 59, 3689-97 **[0100]**
- **DALLAVALLE S ; FERRARI A ; BIASOTTI B et al.** Novel 7-oxyiminomethyl camptothecin derivatives with potent in vitro and in vivo antitumor activity. *J Med Chem,* 2001, vol. 44, 3264-74 **[0100]**

Szabadalmi igénypontok

1. I általános képletű vegyületek:



(I)

ahol

R jelentése F, Cl, Br, I, $-N_3$, NH_2, -NR'R", -COOR', -CONR'R", -NHR"'-NR'R", amelyben R', R" és R"' jelentése lehet H, alkil, aril, arilalkil, acil, alkoxikarbonil, ariloxikarbonil;

R1 jelentése alkil, aminoalkil, hidroxialkil, nitril, -NH-O-alkil, -NH-O-aril, szililalkil;

R2 jelentése hidrogén, hidroxil, alkoxi, aminoalkil;

R3 jelentése hidrogén, alkoxi, aminoalkil,

ahol az alkilcsoportok, acil, alkoxi, aminoalkil vagy -NH-O-alkil tartalmazhatnak 1-8 szénatomot, egyenes vagy elágazó láncban, és az aril- és ariloxicsoportok tartalmazhatnak 5-10 szénatomot;

gyógyszerészetileg elfogadható sóik, enantiomerjeik, diszteereomerjeik és megfelelő keverékek.

2. Az 1. igénypont szerinti vegyület, ahol az alkilcsoportok, acil, alkoxi, aminoalkil vagy -NH-O-alkil 1-4 szénatomot tartalmaznak.

3. A következők alkotta csoportból választott vegyület:

a) tio-kamptotecin;

b) tio-homokamptotecin;

c) tioSN38;

d) tio-topotekán;

e) tioirinotekán;

f) tiogimatekán.

4. Eljárás (I) képletű vegyületek előállítására, amely tartalmazza az 1 reakcióvázlat szerinti lépéseket, ahol:

a) hidroxi prekurzor csoportok védelme;

b) a piridongyűrű átalakítása tiopiridon-gyűrűvé;

c) a védőcsoportok eltávolítása;

I reakcióvázlat



ahol R, R1, R2 és R3 jelentése az előzőekben meghatározott és PG egy OH-védő csoport.

5. Eljárás (I) képletű vegyületek előállítására, amely tartalmazza a II reakcióvázlat szerinti lépéseket, ahol:

a) a prekurzor hidroxicsoportok védelme;

b) származékképzés az 5-ös pozícióban karbanion képzésével és elektrofil reagenssel való reakcióval;

c) a 16a karbonilcsoport átalakítása tiokarbonil-csoporttá;

d) a hidroxilcsoportok védőcsoportjainak eltávolítása;

amelyekben a b) és c) lépések felcserélhetők:



II reakcióvázlat

ahol R, R1, R2 és R3 jelentése az előzőekben meghatározott és PG egy OH-védő csoport.

6. Gyógyszerészeti készítmény, amely tartalmaz (I) képletű vegyületet gyógyszerészetileg elfogadható hordozókkal és segédanyagokkal együtt.

7. A 6. igénypont szerinti gyógyszerészeti készítmény, amely orális vagy parenterális beadásra alkalmas formában van.

8. Az 1-3. igénypontok szerinti vegyület vagy a 6-7. igénypontok szerinti készítmény alkalmazása tumorok kezelésére szolgáló gyógyszer előállítására.

9. A 8. igénypont szerinti alkalmazás, ahol a gyógyszer tömör körülírt tumorok és leukémiák kezelésére szolgál.

10. A 9. igénypont szerinti alkalmazás, ahol a tömör körülírt tumorok és leukémiák a következők közül választottak: a tüdő, petefészek, mell, gyomor, máj, prosztata, lágyszöveti szarkómák, nyelőcső, hasnyálmirigy, fej és nyak tumorai, glioblasztóma, krónikus és akut mielocitás leukémiák.